Terminal Complement Inhibitor Eculizumab in Atypica

New England Journal of Medicine
368, 2169-2181
DOI: 10.1056/nejmoa1208981

Citation Report

#	Article	IF	Citations
1	Guidelines on the Use of Therapeutic Apheresis in Clinical Practiceâ€"Evidenceâ€Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue. Journal of Clinical Apheresis, 2013, 28, 145-284.	0.7	520
2	Clopidogrel with Aspirin in Minor Stroke or Transient Ischemic Attack. New England Journal of Medicine, 2013, 369, 1375-1377.	13.9	15
3	Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome. Drugs, 2013, 73, 2053-2066.	4.9	52
4	HUS and TTP in Children. Pediatric Clinics of North America, 2013, 60, 1513-1526.	0.9	32
5	Atypical Hemolytic Uremic Syndrome. Seminars in Nephrology, 2013, 33, 508-530.	0.6	287
6	The immune system and kidney disease: basic concepts and clinical implications. Nature Reviews Immunology, 2013, 13, 738-753.	10.6	522
7	Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplantation Reviews, 2013, 27, 117-125.	1.2	74
8	Recurrence of glomerulonephritis after renal transplantation. Transplantation Reviews, 2013, 27, 126-134.	1.2	38
9	Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Molecular Immunology, 2013, 56, 199-212.	1.0	70
12	Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions. Nephrology Dialysis Transplantation, 2013, 28, 2899-2907.	0.4	25
13	A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open, 2013, 3, e003573.	0.8	80
14	Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Current Opinion in Nephrology and Hypertension, 2013, 22, 704-712.	1.0	58
15	Eculizumab in Atypical Hemolyticâ€"Uremic Syndrome. New England Journal of Medicine, 2013, 369, 1377-1380.	13.9	61
16	Eculizumab for atypical haemolytic uraemic syndrome: what next?. Nature Reviews Nephrology, 2013, 9, 495-496.	4.1	10
18	Successful Long-Term Treatment of TMA with Eculizumab in a Transplanted Patient with Atypical Hemolytic Uremic Syndrome Due to MCP Mutation. Transplantation, 2013, 96, e74-e76.	0.5	10
19	Anti-C5 as Prophylactic Therapy in Atypical Hemolytic Uremic Syndrome in Living-Related Kidney Transplantation. Transplantation, 2013, 96, e26-e29.	0.5	14
21	Endotheliopathies: Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura, and Preeclampsia. , 2014, , 2767-2787.		1
22	The Platelet as a Target for Damage. , 2014, , 3115-3138.		1

#	Article	IF	Citations
23	Clinical and Renal Biopsy Findings Predicting Outcome in Renal Thrombotic Microangiopathy: A Large Cohort Study from a Single Institute in China. Scientific World Journal, The, 2014, 2014, 1-9.	0.8	25
24	Comprehensive Genetic Analysis of Complement and Coagulation Genes in Atypical Hemolytic Uremic Syndrome. Japanese Journal of Pediatric Nephrology, 2014, 27, 43-44.	0.0	1
26	Meningococcal disease and the complement system. Virulence, 2014, 5, 98-126.	1.8	189
27	Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report. Journal of Medical Case Reports, 2014, 8, 307.	0.4	31
28	First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis. Italian Journal of Pediatrics, 2014, 40, 101.	1.0	8
29	Hemolytic uremic syndrome with simultaneous Shiga toxin producing Escherichia coli and complement abnormalities. BMC Pediatrics, 2014, 14, 278.	0.7	3
30	Complement-Mediated Glomerular Injury in Children. , 2014, , 1-34.		0
31	A Novel Antibody against Human Factor B that Blocks Formation of the C3bB Proconvertase and Inhibits Complement Activation in Disease Models. Journal of Immunology, 2014, 193, 5567-5575.	0.4	14
32	Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management. Turkish Journal of Haematology, 2014, 31, 216-25.	0.2	8
33	Pharmacological treatment of atypical hemolytic-uremic syndrome. Expert Opinion on Orphan Drugs, 2014, 2, 123-135.	0.5	1
34	Complement Mutations in Diacylglycerol Kinase-Îµâ€“Associated Atypical Hemolytic Uremic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1611-1619.	2.2	61
35	Natural History of Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome. Seminars in Thrombosis and Hemostasis, 2014, 40, 866-873.	1.5	33
36	Differing Tales of Two Patients after Receiving a Kidney Transplant from a Donor with Disseminated Intravascular Coagulation. Case Reports in Transplantation, 2014, 2014, 1-5.	0.1	0
37	Atypical haemolytic uraemic syndrome associated with a CD46 mutation triggered by Shigella flexneri. CKJ: Clinical Kidney Journal, 2014, 7, 286-288.	1.4	12
38	Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrology Dialysis Transplantation, 2014, 29, 565-572.	0.4	93
39	Complement activation in the tubulointerstitium: AKI, CKD, and in between. Kidney International, 2014, 86, 663-666.	2.6	11
40	Anti-factor H autoantibody-associated hemolytic uremic syndrome: the earlier diagnosed and treated, the better. Kidney International, 2014, 85, 1019-1022.	2.6	12
42	Use of eculizumab in refractory gemcitabineâ€induced thrombotic microangiopathy. British Journal of Haematology, 2014, 164, 894-896.	1.2	26

#	Article	IF	Citations
43	Post transplant thrombotic microangiopathy. Indian Journal of Transplantation, 2014, 8, 113-120.	0.0	2
44	Deficiencies of the Complement System. , 2014, , 731-763.		6
45	Targeted Therapy with Eculizumab for Inherited CD59 Deficiency. New England Journal of Medicine, 2014, 370, 90-92.	13.9	55
46	Malignancy and thrombotic microangiopathy or atypical haemolytic and uraemic syndrome?. British Journal of Haematology, 2014, 166, 802-805.	1.2	11
47	How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. British Journal of Haematology, 2014, 164, 759-766.	1.2	128
48	Ethical dilemmas about orphan drugs for orphan diseases. Journal of Paediatrics and Child Health, 2014, 50, 249-250.	0.4	8
49	Antiphospholipid syndrome in renal transplantation. Nephrology, 2014, 19, 177-185.	0.7	21
52	Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation. Pediatric Transplantation, 2014, 18, E185-9.	0.5	8
53	Protecting the kidney from complement: atypical haemolytic uraemic syndrome. Clinical Medicine, 2014, 14, s89-s94.	0.8	1
54	Current treatment of atypical hemolytic uremic syndrome. Intractable and Rare Diseases Research, 2014, 3, 34-45.	0.3	50
55	Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation. International Journal of Hematology, 2014, 100, 437-442.	0.7	41
56	The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia. Orphanet Journal of Rare Diseases, 2014, 9, 98.	1.2	54
57	Atypical Hemolytic Uremic Syndrome Recurrence After Kidney Transplantation. Transplantation, 2014, 98, 1205-1212.	0.5	47
58	Anti-RNA Polymerase III Antibodies in the Diagnosis of Scleroderma Renal Crisis in the Absence of Skin Disease. Journal of Clinical Rheumatology, 2014, 20, 379-382.	0.5	13
59	Complement Factor B Mutations in Atypical Hemolytic Uremic Syndromeâ€"Disease-Relevant or Benign?. Journal of the American Society of Nephrology: JASN, 2014, 25, 2053-2065.	3.0	107
60	Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome. Advances in Hematology, 2014, 2014, 1-7.	0.6	19
61	Insights From the Use in Clinical Practice of Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome Affecting the Native Kidneys: An Analysis of 19 Cases. American Journal of Kidney Diseases, 2014, 63, 40-48.	2.1	74
62	Anti-Complement Therapy for Glomerular Diseases. Advances in Chronic Kidney Disease, 2014, 21, 152-158.	0.6	15

#	Article	IF	Citations
63	Eculizumab Therapy in Children with Severe Hematopoietic Stem Cell Transplantationâ€“Associated Thrombotic Microangiopathy. Biology of Blood and Marrow Transplantation, 2014, 20, 518-525.	2.0	218
64	Making sense of the spectrum of glomerular disease associated with complement dysregulation. Pediatric Nephrology, 2014, 29, 1883-1894.	0.9	3
65	Haemolytic uremic syndrome following fire ant bites. BMC Nephrology, 2014, 15, 5.	0.8	11
66	Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood, 2014, 123, 3733-3738.	0.6	130
67	Hemolytic uremic syndrome. Seminars in Immunopathology, 2014, 36, 399-420.	2.8	136
68	Eculizumab Therapy. Biology of Blood and Marrow Transplantation, 2014, 20, 438-439.	2.0	1
70	Complement modulation in solid-organ transplantation. Transplantation Reviews, 2014, 28, 119-125.	1.2	20
71	Plasma Exchange for Kidney Disease: What Is the Best Evidence?. Advances in Chronic Kidney Disease, 2014, 21, 217-227.	0.6	19
72	Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement. Pediatric Nephrology, 2014, 29, 1103-1106.	0.9	23
73	Eculizumab as First-Line Therapy for Atypical Hemolytic Uremic Syndrome. Pediatrics, 2014, 133, e1759-e1763.	1.0	22
74	Cryptic Activity of Atypical Hemolytic Uremic Syndrome and Eculizumab Treatment. Pediatrics, 2014, 133, e1769-e1771.	1.0	10
75	Genetics of Atypical Hemolytic Uremic Syndrome (aHUS). Seminars in Thrombosis and Hemostasis, 2014, 40, 422-430.	1.5	122
76	Treatment of Enterohemorrhagic Escherichia coliâ€“Induced Hemolytic Uremic Syndrome (eHUS). Seminars in Thrombosis and Hemostasis, 2014, 40, 508-516.	1.5	40
77	Diagnosis and Treatment of the Hemolytic Uremic Syndrome Disease Spectrum in Developing Regions. Seminars in Thrombosis and Hemostasis, 2014, 40, 478-486.	1.5	25
78	Complement Factor H-Antibodyâ€“Associated Hemolytic Uremic Syndrome: Pathogenesis, Clinical Presentation, and Treatment. Seminars in Thrombosis and Hemostasis, 2014, 40, 431-443.	1.5	41
79	Treatment of C3 Glomerulopathy with Complement Blockers. Seminars in Thrombosis and Hemostasis, 2014, 40, 472-477.	1.5	56
80	Macrovascular involvement in a child with atypical hemolytic uremic syndrome. Pediatric Nephrology, 2014, 29, 1273-1277.	0.9	17
81	Successful discontinuation of eculizumab therapy in a patient with aHUS. Annals of Hematology, 2014, 93, 1423-1425.	0.8	19

#	Article	IF	Citations
82	Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the joint committee of the Japanese society of nephrology and the Japan pediatric society. Clinical and Experimental Nephrology, 2014, 18, 4-9.	0.7	24
83	Time to change the definition of hemolytic uremic syndrome. European Journal of Internal Medicine, 2014, 25, e29.	1.0	22
84	Cardiovascular complications in atypical haemolytic uraemic syndrome. Nature Reviews Nephrology, 2014, 10, 174-180.	4.1	63
85	Diagnosis and management of complement mediated thrombotic microangiopathies. Blood Reviews, 2014, 28, 67-74.	2.8	43
86	14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Autoimmunity Reviews, 2014, 13, 685-696.	2.5	290
87	Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome. Immunology Letters, 2014, 160, 163-171.	1.1	50
88	Liverâ€“kidney transplantation to cure atypical HUS: still an option post-eculizumab?. Pediatric Nephrology, 2014, 29, 329-332.	0.9	50
89	Thrombotic microangiopathies. Seminars in Arthritis and Rheumatism, 2014, 43, 797-805.	1.6	34
91	Phenotypic Expansion of DGKE-Associated Diseases. Journal of the American Society of Nephrology: JASN, 2014, 25, 1408-1414.	3.0	59
92	A Mechanistic Approach to the Diagnosis and Management of Atypical Hemolytic Uremic Syndrome. Transfusion Medicine Reviews, 2014, 28, 187-197.	0.9	35
94	Factors influencing long-term outcome after kidney transplantation. Transplant International, 2014, 27, 19-27.	0.8	176
95	Innovative therapeutic approach: Sequential treatment with plasma exchange and eculizumab in a pregnant woman affected by atypical hemolytic-uremic syndrome. Transfusion and Apheresis Science, 2014, 51, 134-136.	0.5	21
96	Syndromes of Thrombotic Microangiopathy. New England Journal of Medicine, 2014, 371, 654-666.	13.9	972
97	Ten-year advances in immunopathology of glomerulonephritis: translated into patientsâ€™ care or lost in translation?. Seminars in Immunopathology, 2014, 36, 377-379.	2.8	5
98	An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatric Nephrology, 2014, 29, 1967-1978.	0.9	95
99	Eculizumab: a guide to its use in atypical haemolytic uraemic syndrome. Drugs and Therapy Perspectives, 2014, 30, 166-172.	0.3	1
100	How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood, 2014, 123, 2478-2484.	0.6	115
101	Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency. Pediatric Nephrology, 2014, 29, 2415-2419.	0.9	18

#	Article	IF	Citations
102	Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab. Nephrology Dialysis Transplantation, 2014, 29, iv131-iv141.	0.4	65
103	Disorders of complement regulation. Drug Discovery Today: Disease Models, 2014, 11, 29-35.	1.2	0
104	Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis. Journal of Thrombosis and Haemostasis, 2014, 12, 1437-1439.	1.9	11
105	Spectrum of Complement-Mediated Thrombotic Microangiopathies: Pathogenetic Insights Identifying Novel Treatment Approaches. Seminars in Thrombosis and Hemostasis, 2014, 40, 444-464.	1.5	117
106	Atypical Hemolytic Uremic Syndrome. Advances in Pediatrics, 2014, 61, 335-356.	0.5	10
107	Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the <scp>J</scp>oint <scp>C</scp>ommittee of the <scp>J</scp>apanese <scp>S</scp>ociety of <scp>N</scp>ephrology and the <scp>J</scp>apan <scp>P</scp>ediatric <scp>S</scp>ociety. Pediatrics International, 2014, 56, 1-5.	0.2	29
108	Acquired Bleeding Disorders. Emergency Medicine Clinics of North America, 2014, 32, 691-713.	0.5	9
109	Complement the hemostatic system: an intimate relationship. Thrombosis Research, 2014, 133, S117-S121.	0.8	12
110	Whole-exome sequencing identifies rare, functional CFH variants in families with macular degeneration. Human Molecular Genetics, 2014, 23, 5283-5293.	1.4	95
111	Hemolytic Uremic Syndrome: Toxins, Vessels, and Inflammation. Frontiers in Medicine, 2014, 1, 42.	1.2	10
112	A 'silent', new polymorphism of factor H and apparent de novo atypical haemolytic uraemic syndrome after kidney transplantation. BMJ Case Reports, 2014, 2014, bcr2014207630-bcr2014207630.	0.2	6
113	Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia. Blood, 2014, 124, 3503-3505.	0.6	23
114	TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood, 2014, 123, 4015-4022.	0.6	132
115	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood, 2014, 124, 1715-1726.	0.6	288
116	Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood, 2014, 124, 645-653.	0.6	318
117	Eculizumab fails to inhibit generation of C5a in vivo. Blood, 2014, 124, 3502-3503.	0.6	23
118	Thrombotic microangiopathy in a patient with adultâ€onset <scp>S</scp>till's disease. Transfusion, 2014, 54, 2983-2987.	0.8	6
119	Complement in hemolytic anemia. Hematology American Society of Hematology Education Program, 2015, 2015, 385-391.	0.9	9

#	Article	IF	Citations
120	Atypical hemolytic uraemic syndrome. Medicina ClÃ¬nica (English Edition), 2015, 145, 438-445.	0.1	2
121	Syndromes of thrombotic microangiopathy associated with pregnancy. Hematology American Society of Hematology Education Program, 2015, 2015, 644-648.	0.9	79
122	Biologic agents in the treatment of glomerulonephritides. Nephrology, 2015, 20, 767-787.	0.7	3
123	Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the <scp>A</scp>ustralian compassionate access cohort. Internal Medicine Journal, 2015, 45, 1054-1065.	0.5	25
124	Complement in hemolytic anemia. Blood, 2015, 126, 2459-2465.	0.6	84
125	Atypical HUS may become a diagnosis of inclusion. Blood, 2015, 125, 3525-3526.	0.6	2
126	Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood, 2015, 125, 3253-3262.	0.6	151
127	7. Thrombotic Microangiopathy: HUS and Atypical HUS. The Journal of the Japanese Society of Internal Medicine, 2015, 104, 1959-1963.	0.0	0
128	Refractory atypical hemolytic uremic syndrome with monoclonal gammopathy responsive to bortezomib-based therapy. Clinical Nephrology, 2015, 83 (2015), 363-369.	0.4	24
129	Progression to end-stage renal disease is reduced with eculizumab in patients with atypical haemolytic uraemic syndrome. Critical Care, 2015, 19, .	2.5	0
130	Early initiation of eculizumab treatment in patients with atypical haemolytic uraemic syndrome improves long-term outcomes: a pooled analysis of clinical trials. Critical Care, 2015, 19, .	2.5	0
131	Adjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: a randomized controlled trial. Journal of Neuroinflammation, 2015, 12, 149.	3.1	26
133	The global aHUS registry: methodology and initial patient characteristics. BMC Nephrology, 2015, 16, 207.	0.8	52
134	Solving the puzzle of posthospital recovery: What is the role of the individual physician?. Journal of Hospital Medicine, 2015, 10, 697-700.	0.7	4
135	Overactivation of Complement Alternative Pathway in Postpartum Atypical Hemolytic Uremic Syndrome Patients with Renal Involvement. American Journal of Reproductive Immunology, 2015, 74, 345-356.	1.2	17
136	Role of the Skin Biopsy in the Diagnosis of Atypical Hemolytic Uremic Syndrome. American Journal of Dermatopathology, 2015, 37, 349-359.	0.3	35
137	Diagnosing kidney disease in the genetic era. Current Opinion in Nephrology and Hypertension, 2015, 24, 1.	1.0	8
138	Lifeâ€threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab. Transfusion, 2015, 55, 2398-2403.	0.8	43

#	Article	IF	Citations
139	Autoantibodies and their potential roles in diseases of the nervous system. Clinical and Experimental Neuroimmunology, 2015, 6, 370-386.	0.5	7
140	The Differential Diagnosis of Thrombocytopenia in Pregnancy. Deutsches Ärzteblatt International, 2015, 112, 795-802.	0.6	40
141	Case report of atypical hemolytic uremic syndrome with retinal arterial and venous occlusion treated with eculizumab. International Medical Case Reports Journal, 2015, 8, 235.	0.3	19
142	Hemolytic uremic syndrome. Turk Pediatri Arsivi, 2015, 50, 73-81.	0.9	38
143	Acute Systolic Heart Failure Associated with Complement-Mediated Hemolytic Uremic Syndrome. Case Reports in Hematology, 2015, 2015, 1-3.	0.3	5
144	Role of Complement and Complement Regulatory Proteins in the Complications of Diabetes. Endocrine Reviews, 2015, 36, 272-288.	8.9	127
145	Clinicopathologic Characteristics and Outcomes of Renal Thrombotic Microangiopathy in Anti-Neutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 750-758.	2.2	30
146	Atypical hemolytic uremic syndrome: from diagnosis to treatment. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1679-88.	1.4	21
147	Soluble C5b-9 as a Biomarker for Complement Activation in Atypical Hemolytic Uremic Syndrome. American Journal of Kidney Diseases, 2015, 65, 968-969.	2.1	55
148	Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report. Journal of Medical Case Reports, 2015, 9, 92.	0.4	11
149	Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Antiâ€“Factor H IgAÎ» Antibody. American Journal of Kidney Diseases, 2015, 66, 331-336.	2.1	21
150	Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1011-1019.	2.2	47
151	New combinedCFH/MCPmutations and a rare clinical course in atypical haemolytic uraemic syndrome: TableÂ1.. CKJ: Clinical Kidney Journal, 2015, 8, 695-697.	1.4	2
152	An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document. Nefrologia, 2015, 35, 421-447.	0.2	77
153	Eculizumab as rescue therapy in severe resistant lupus nephritis: Fig. 1. Rheumatology, 2015, 54, kev307.	0.9	40
154	Good Pharma. , 2015, , .		9
155	Thrombotic microangiopathy: expanding genetic, clinical and therapeutic spectra and the need for worldwide implementation of recent advances. CKJ: Clinical Kidney Journal, 2015, 8, 686-689.	1.4	3
156	Paediatric nephrology: The last 50 years. Journal of Paediatrics and Child Health, 2015, 51, 94-97.	0.4	2

#	Article	IF	Citations
157	Identification and Management of Atypical Hemolytic Uremic Syndrome Immediately Post-Heart Transplantation. Journal of Cardiac Surgery, 2015, 30, 373-375.	0.3	4
158	Endâ€stage renal disease from hemolytic uremic syndrome in the <scp>U</scp>nited <scp>S</scp>tates, 1995â€“2010. Hemodialysis International, 2015, 19, 521-530.	0.4	1
159	Current insights into thrombotic microangiopathies: Thrombotic thrombocytopenic purpura and pregnancy. Thrombosis Research, 2015, 135, S30-S33.	0.8	32
160	Rare inherited disorders with renal involvementâ€”approach to the patient. Kidney International, 2015, 87, 901-908.	2.6	18
161	Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney International, 2015, 87, 1061-1073.	2.6	342
162	Spectrum and Management of Complement Immunodeficiencies (Excluding Hereditary Angioedema) Across Europe. Journal of Clinical Immunology, 2015, 35, 199-205.	2.0	40
163	Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy. Journal of the American Society of Nephrology: JASN, 2015, 26, 2239-2247.	3.0	97
164	Molecules Great and Small. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1636-1650.	2.2	217
165	Safe and effective use of eculizumab in the treatment of severe Shiga toxinEscherichia coli-associated hemolytic uremic syndrome. American Journal of Health-System Pharmacy, 2015, 72, 117-120.	0.5	14
166	Podocyte dysfunction in atypical haemolytic uraemic syndrome. Nature Reviews Nephrology, 2015, 11, 245-252.	4.1	49
167	Quality of life one year postâ€Shiga toxinâ€producing Escherichia coli O104 infection â€“ A prospective cohort study. Neurogastroenterology and Motility, 2015, 27, 370-378.	1.6	5
168	Complement regulators in human disease: lessons from modern genetics. Journal of Internal Medicine, 2015, 277, 294-305.	2.7	60
169	Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension. Pediatric Nephrology, 2015, 30, 603-608.	0.9	14
170	Eculizumab hepatotoxicity in pediatric aHUS. Pediatric Nephrology, 2015, 30, 775-781.	0.9	39
171	A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab. Pediatric Nephrology, 2015, 30, 1039-1042.	0.9	15
172	Complement regulator CD46: genetic variants and disease associations. Human Genomics, 2015, 9, 7.	1.4	87
173	Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney International, 2015, 88, 1153-1160.	2.6	130
174	Immune-mediated pathology in Duchenne muscular dystrophy. Science Translational Medicine, 2015, 7, 299rv4.	5.8	209

#	Article	IF	Citations
175	From the nephrologist's point of view: diversity of causes and clinical features of acute kidney injury. CKJ: Clinical Kidney Journal, 2015, 8, 405-414.	1.4	39
176	Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clinical Immunology, 2015, 160, 237-243.	1.4	42
177	Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway. Journal of the American Society of Nephrology: JASN, 2015, 26, 2917-2929.	3.0	84
178	Primary and Secondary Thrombotic Microangiopathy Referred to a Single Plasma Exchange Center for Suspected Thrombotic Thrombocytopenic Purpura: 2000-2011. American Journal of Nephrology, 2015, 41, 429-437.	1.4	13
179	Protocolo diagnÃ³stico del sÃndrome hemolÃtico-urÃ©mico. Medicine, 2015, 11, 4935-4937.	0.0	0
180	Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome. Molecular Immunology, 2015, 67, 276-286.	1.0	49
181	Monoclonal antibodies for renal diseases: current concepts and ongoing treatments. Expert Opinion on Biological Therapy, 2015, 15, 1119-1143.	1.4	16
182	Autoimmuneâ€type atypical hemolytic uremic syndrome treated with eculizumab as firstâ€line therapy. Pediatrics International, 2015, 57, 313-317.	0.2	14
183	Continuing Progress in Vasculitis Research. Abstracts of the 17th International Vasculitis & ANCA WorkshopLondon, April 19-22, 2015: Abstracts. Nephron, 2015, 129, 1-44.	0.9	13
184	Primary disease recurrenceâ€"effects on paediatric renal transplantation outcomes. Nature Reviews Nephrology, 2015, 11, 371-384.	4.1	34
185	Modified Ham test for atypical hemolytic uremic syndrome. Blood, 2015, 125, 3637-3646.	0.6	88
186	Remission of aHUS neurological damage with eculizumab. CKJ: Clinical Kidney Journal, 2015, 8, 232-236.	1.4	7
187	Cerebral autoregulation testing in a porcine model of intravenously administrated E. coli induced fulminant sepsis. Critical Care, 2015, 19, P1-P578.	2.5	5
188	The complement system and adverse pregnancy outcomes. Molecular Immunology, 2015, 67, 56-70.	1.0	126
189	Managing atypical hemolytic uremic syndrome: chapter 2. Kidney International, 2015, 87, 882-884.	2.6	11
190	Case Report: Benefits and Challenges of Long-term Eculizumab in Atypical Hemolytic Uremic Syndrome. Pediatrics, 2015, 135, e1506-e1509.	1.0	35
191	The Expanding Role of Therapeutic Antibodies. International Reviews of Immunology, 2015, 34, 202-264.	1.5	22
192	Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome. Pathologie Et Biologie, 2015, 63, 136-143.	2.2	42

#	Article	IF	Citations
193	Atypical aHUS: State of the art. Molecular Immunology, 2015, 67, 31-42.	1.0	236
194	Diarrhoea in the critically ill. Current Opinion in Critical Care, 2015, 21, 142-153.	1.6	54
195	Home-based management of patients with atrial fibrillation. Lancet, The, 2015, 385, 752-753.	6.3	2
196	Thrombotic Microangiopathy. Hematology/Oncology Clinics of North America, 2015, 29, 541-559.	0.9	25
197	Current and Future Pharmacologic Complement Inhibitors. Hematology/Oncology Clinics of North America, 2015, 29, 561-582.	0.9	30
198	Rare diseases and effective treatments: are we delivering?. Lancet, The, 2015, 385, 750-752.	6.3	46
199	Nephrology researchâ€"the past, present and future. Nature Reviews Nephrology, 2015, 11, 677-687.	4.1	23
200	Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab. American Journal of Kidney Diseases, 2015, 66, 1067-1070.	2.1	25
201	The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring. Thrombosis Research, 2015, 136, 851-854.	0.8	27
202	The Pharmacokinetics of Intradialytic Administration of Eculizumab in an Infant. American Journal of Kidney Diseases, 2015, 66, 1105-1106.	2.1	5
203	Complement, a target for therapy in inflammatory and degenerative diseases. Nature Reviews Drug Discovery, 2015, 14, 857-877.	21.5	357
204	Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis. Leukemia Research Reports, 2015, 4, 36-38.	0.2	17
205	Timing of eculizumab therapy for C3 glomerulonephritis. CKJ: Clinical Kidney Journal, 2015, 8, 449-452.	1.4	15
206	Hematopoietic stem cell transplantationâ€associated thrombotic microangiopathy accompanied by renal arteriolar C4d deposition. Pediatric Transplantation, 2015, 19, E97-100.	0.5	15
207	Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions. Advances in Experimental Medicine and Biology, 2015, 865, 19-42.	0.8	48
208	ActualizaciÃ³n en sÃndrome hemolÃtico urÃ©mico atÃpico: diagnÃ³stico y tratamiento. Documento de consenso. Nefrologia, 2015, 35, 421-447.	0.2	188
209	Thrombotic Microangiopathies and Their Distinction from TTP. , 2015, , 129-139.		0
210	Thrombocytopenia-Associated Multiple Organ Failure and Acute Kidney Injury. Critical Care Clinics, 2015, 31, 661-674.	1.0	42

#	Article	IF	Citations
211	ADAMTS13. , 2015, , .		1
213	Thrombotic Microangiopathy as a Cause of Chronic Kidney Transplant Dysfunction: Case Report Demonstrating Successful Treatment withÂEculizumab. Transplantation Proceedings, 2015, 47, 2258-2261.	0.3	6
214	Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. MAbs, 2015, 7, 1205-1211.	2.6	67
215	Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Therapeutic Advances in Hematology, 2015, 6, 171-185.	1.1	15
216	The emerging role of complement inhibitors in transplantation. Kidney International, 2015, 88, 967-973.	2.6	39
217	Eculizumab in Pediatric Dense Deposit Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1773-1782.	2.2	51
218	Pharmacokinetics and Pharmacokineticâ€“Pharmacodynamic Relationships of Monoclonal Antibodies in Children. Clinical Pharmacokinetics, 2015, 54, 35-80.	1.6	34
219	Thrombotic Microangiopathy in Systemic Lupus Erythematosus: Efficacy of Eculizumab. American Journal of Kidney Diseases, 2015, 65, 127-130.	2.1	69
221	Successful use of eculizumab for treatment of an acute hemolytic reaction after <scp>ABO</scp>â€incompatible red blood cell transfusion. Transfusion, 2015, 55, 605-610.	0.8	27
222	Success of eculizumab in the treatment of atypical hemolytic uremic syndrome. Pediatric Nephrology, 2015, 30, 783-789.	0.9	18
224	New Biologics for Glomerular Disease on the Horizon. Nephron Clinical Practice, 2015, 128, 283-291.	2.3	6
225	Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Translational Research, 2015, 165, 306-320.	2.2	64
226	Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission. Clinical and Experimental Immunology, 2015, 181, 306-313.	1.1	47
227	Approach to the Patient with Chronic Glomerular Disease. , 2015, , 443-454.		1
228	The Root of This Evil: Microangiopathic Hemolytic Anemia and Renal Failure. American Journal of Medicine, 2015, 128, 21-23.	0.6	2
229	Recovery of renal function after long-term dialysis and resolution of cardiomyopathy in a patient with aHUS receiving eculizumab. BMJ Case Reports, 2016, 2016, bcr2015213928.	0.2	11
230	Atypical Haemolytic Uraemic Syndrome Associated with Cabazitaxel in Advanced Prostate Cancer. Medical Case Reports (Wilmington, Del), 2016, 2, .	0.1	3
231	Pregnant Woman with Atypical Hemolytic Uremic Syndrome Delivered a Healthy Newborn under Eculizumab Treatment. Case Reports in Nephrology and Dialysis, 2016, 6, 143-148.	0.3	20

#	Article	IF	Citations
232	Eculizumabâ˜†. , 2016, , .		0
233	Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab. Hematology Reports, 2016, 8, 6625.	0.3	21
234	Association among Complement Factor H Autoantibodies, Deletions of CFHR, and the Risk of Atypical Hemolytic Uremic Syndrome. International Journal of Environmental Research and Public Health, 2016, 13, 1209.	1.2	10
235	Acute Kidney Injury, Recurrent Seizures, and Thrombocytopenia in a Young Patient with Lupus Nephritis: A Diagnostic Dilemma. Case Reports in Nephrology, 2016, 2016, 1-8.	0.2	4
236	Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern. Case Reports in Nephrology, 2016, 2016, 1-7.	0.2	2
237	Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy. Case Reports in Hematology, 2016, 2016, 1-3.	0.3	17
238	Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. Journal of Blood Medicine, 2016, 7, 39.	0.7	20
239	NETosing Neutrophils Activate Complement Both on Their Own NETs and Bacteria via Alternative and Non-alternative Pathways. Frontiers in Immunology, 2016, 7, 137.	2.2	123
240	Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. Journal of Korean Medical Science, 2016, 31, 1516.	1.1	21
241	Guidelines on the Use of Therapeutic Apheresis in Clinical Practiceâ€“Evidenceâ€Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. Journal of Clinical Apheresis, 2016, 31, 149-338.	0.7	384
243	Adult Postâ€“Kidney Transplant Familial Atypical Hemolytic Uremic Syndrome Successfully Treated With Eculizumab: A Case Report and Literature Review. American Journal of Therapeutics, 2016, 23, e1110-e1115.	0.5	2
244	Disease Recurrence After Early Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome With Complement C3 I1157T Mutation. Journal of Pediatric Hematology/Oncology, 2016, 38, e137-e139.	0.3	13
245	Complement inhibition as potential new therapy for antibody-mediated rejection. Transplant International, 2016, 29, 392-402.	0.8	28
247	Nephrotic-Range Proteinuria and Peripheral Edema in a Child: Not Only Idiopathic Nephrotic Syndrome. Case Reports in Nephrology and Dialysis, 2016, 6, 120-127.	0.3	7
248	Developing Treatments for Chronic Kidney Disease in the 21st Century. Seminars in Nephrology, 2016, 36, 436-447.	0.6	45
249	Atypical hemolytic uremic syndrome. Hematology American Society of Hematology Education Program, 2016, 2016, 217-225.	0.9	44
251	Immunisation of the immunocompromised child. Journal of Infection, 2016, 72, S13-S22.	1.7	15
252	Examining coagulation-complement crosstalk: complement activation and thrombosis. Thrombosis Research, 2016, 141, S50-S54.	0.8	57

#	Article	IF	Citations
253	Late onset of de novo atypical hemolyticâ€“uremic syndrome presented on a simultaneous pancreas and kidney transplant recipient successfully treated with eculizumab. Nefrologia, 2016, 36, 328-329.	0.2	2
254	Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. American Journal of Kidney Diseases, 2016, 68, 84-93.	2.1	230
255	Thrombotic thrombocytopenic purpura: gaining knowledge. Lancet Haematology,the, 2016, 3, e210-e211.	2.2	3
256	Atypical hemolytic uremic syndrome in intensive care: Case report in an adult. Medicina Intensiva (English Edition), 2016, 40, 189-191.	0.1	0
257	Atypical hemolytic uremic syndrome: a clinical conundrum. Pediatric Nephrology, 2016, 31, 1615-1624.	0.9	9
258	Pregnancy-related thrombotic microangiopathies: Clues from complement biology. Transfusion and Apheresis Science, 2016, 54, 199-202.	0.5	59
259	The alternative pathway of complement and the thrombotic microangiopathies. Transfusion and Apheresis Science, 2016, 54, 220-231.	0.5	13
260	Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab. Nephrology Dialysis Transplantation, 2016, 31, 2122-2130.	0.4	72
261	Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999â€“2008. BMC Infectious Diseases, 2016, 16, 285.	1.3	36
262	Late onset of de novo atypical hemolyticâ€“uremic syndrome presented on a simultaneous pancreas and kidney transplant recipient successfully treated with eculizumab. Nefrologia, 2016, 36, 328-329.	0.2	1
263	Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey. Transfusion and Apheresis Science, 2016, 55, 357-362.	0.5	8
264	Effetti collaterali delle bioterapie nella sclerosi multipla e nelle malattie correlate. EMC - Neurologia, 2016, 16, 1-10.	0.0	0
265	Plasmapheresis for the treatment of kidneyÂdiseases. Kidney International, 2016, 90, 974-984.	2.6	43
266	How randomised trials have improved the care of children with kidney disease. Pediatric Nephrology, 2016, 31, 2191-2200.	0.9	0
267	Thrombotic Microangiopathy in the Setting of HIV Infection: A Case Report and Review of the Differential Diagnosis and Therapy. AIDS Patient Care and STDs, 2016, 30, 359-364.	1.1	15
268	Does Anticomplement Therapy Have a Role in the Management of Malignant Hypertension?. Journal of Clinical Hypertension, 2016, 18, 359-360.	1.0	9
269	Clinical guides for atypical hemolytic uremic syndrome in Japan. Pediatrics International, 2016, 58, 549-555.	0.2	19
270	The role of ADAMTSâ€13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies. Journal of Thrombosis and Haemostasis, 2016, 14, 175-185.	1.9	31

#	Article	IF	Citations
271	Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature. Clinical Case Reports (discontinued), 2016, 4, 773-776.	0.2	7
272	Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clinic Proceedings, 2016, 91, 1189-1211.	1.4	55
273	Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome. , 2016, , 531-547.		0
274	PASylated Coversin, a C5-Specific Complement Inhibitor with Extended Pharmacokinetics, Shows Enhanced Anti-Hemolytic Activity in Vitro. Bioconjugate Chemistry, 2016, 27, 2359-2371.	1.8	53
276	Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome Microangiopathy in Pregnancy. Seminars in Thrombosis and Hemostasis, 2016, 42, 774-779.	1.5	35
277	First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients. Paediatric Drugs, 2016, 18, 413-420.	1.3	10
278	Clinical guides for atypical hemolytic uremic syndrome in Japan. Clinical and Experimental Nephrology, 2016, 20, 536-543.	0.7	41
279	Complement-Mediated Glomerular Diseases: A Tale of 3 Pathways. Kidney International Reports, 2016, 1, 148-155.	0.4	39
280	Anti-complement-factor H-associated glomerulopathies. Nature Reviews Nephrology, 2016, 12, 563-578.	4.1	94
281	Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation. Advances in Clinical Chemistry, 2016, 77, 1-75.	1.8	36
282	Critical Care for the Obstetrician and Gynecologist. Obstetrics and Gynecology Clinics of North America, 2016, 43, 611-622.	0.7	6
283	Thrombocytopenia. Primary Care - Clinics in Office Practice, 2016, 43, 543-557.	0.7	35
284	Endothelial cells: source, barrier, and target of defensive mediators. Immunological Reviews, 2016, 274, 307-329.	2.8	88
285	Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome. Thrombosis Journal, 2016, 14, 19.	0.9	22
286	An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the Global aHUS Registry. Orphanet Journal of Rare Diseases, 2016, 11, 154.	1.2	22
287	Acute kidney injury in a patient with hemolytic anemia and thrombocytopenia. JAAPA: Official Journal of the American Academy of Physician Assistants, 2016, 29, 1-4.	0.1	0
288	Complete remission of thrombotic microangiopathy after treatment with eculizumab in a patient with non-Shiga toxin-associated bacterial enteritis. Medicine (United States), 2016, 95, e4104.	0.4	7
289	Can eculizumab be discontinued in aHUS?. Medicine (United States), 2016, 95, e4330.	0.4	19

#	Article	IF	Citations
290	Irreversible severe kidney injury and anuria in a 3-month-old girl with atypical haemolytic uraemic syndrome under administration of eculizumab. Nephrology, 2016, 21, 261-265.	0.7	3
291	Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Current Opinion in Infectious Diseases, 2016, 29, 319-329.	1.3	115
292	Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer. Journal of Oncology Practice, 2016, 12, 523-530.	2.5	64
293	All Things Complement. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1856-1866.	2.2	61
294	Targeting the complement cascade: novel treatments coming down the pike. Kidney International, 2016, 90, 746-752.	2.6	41
295	Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab. Journal of Immunological Methods, 2016, 435, 60-67.	0.6	6
296	Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3. Nefrologia, 2016, 36, 72-75.	0.2	2
297	Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3. Nefrologia, 2016, 36, 72-75.	0.2	1
298	Diabetic ketoacidosis presenting with atypical hemolytic uremic syndrome associated with a variant of complement factor B in an adult: a case report. Journal of Medical Case Reports, 2016, 10, 38.	0.4	4
299	Cancer and Thrombotic Microangiopathy. Journal of Oncology Practice, 2016, 12, 531-532.	2.5	4
300	Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future. Seminars in Immunology, 2016, 28, 223-240.	2.7	36
301	New insight into the effects of heparinoids on complement inhibition by C1-inhibitor. Clinical and Experimental Immunology, 2016, 184, 378-388.	1.1	37
302	Successful treatment of neonatal atypical hemolytic uremic syndrome with C5 monoclonal antibody. Archives De Pediatrie, 2016, 23, 283-286.	0.4	5
304	Emerging Therapies in Antiphospholipid Syndrome. Current Rheumatology Reports, 2016, 18, 22.	2.1	37
305	Post-bone marrow transplant thrombotic microangiopathy. Bone Marrow Transplantation, 2016, 51, 891-897.	1.3	26
306	Pregnancy-Associated Atypical Hemolytic-Uremic Syndrome. AJP Reports, 2016, 06, e125-e128.	0.4	34
307	Eculizumab in children with hemolytic uremic syndrome. Kidney International, 2016, 89, 537-538.	2.6	2
308	The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica, 2016, 101, 115-208.	1.7	67

#	Article	IF	Citations
309	Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney International, 2016, 89, 701-711.	2.6	210
310	Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase. Journal of Biological Chemistry, 2016, 291, 8214-8230a.	1.6	12
311	Atypical hemolytic uremic syndrome in intensive care: Case report in an adult. Medicina Intensiva, 2016, 40, 188-190.	0.4	1
312	Direct evidence of complement activation in HELLP syndrome: A link toÂatypical hemolytic uremic syndrome. Experimental Hematology, 2016, 44, 390-398.	0.2	80
313	An Algorithmic Approach to the Diagnosis and Management of the Thrombotic Microangiopathies. American Journal of Clinical Pathology, 2016, 145, 152-154.	0.4	10
314	Pathology Consultation on the Diagnosis and Treatment of Thrombotic Microangiopathies (TMAs). American Journal of Clinical Pathology, 2016, 145, 158-165.	0.4	34
315	Biologics for the treatment of autoimmune renal diseases. Nature Reviews Nephrology, 2016, 12, 217-231.	4.1	45
316	Renal Involvement in Children with HUS. , 2016, , 1489-1521.		4
317	The long-term outcomes of atypical haemolytic uraemic syndrome: a national surveillance study. Archives of Disease in Childhood, 2016, 101, 387-391.	1.0	13
318	Extrarenal Progenitor Cells Do Not Contribute to Renal Endothelial Repair. Journal of the American Society of Nephrology: JASN, 2016, 27, 1714-1726.	3.0	30
320	Variable Eculizumab Clearance Requires PharmacodynamicÂMonitoring to Optimize TherapyÂforÂThrombotic Microangiopathy after HematopoieticÂStem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 307-315.	2.0	125
321	Current therapeutic developments in atrophic age-related macular degeneration. British Journal of Ophthalmology, 2016, 100, 122-127.	2.1	65
322	Liver transplantation for aHUS: still needed in the eculizumab era?. Pediatric Nephrology, 2016, 31, 759-768.	0.9	22
323	CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS). Pediatric Nephrology, 2016, 31, 157-161.	0.9	18
324	Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 12-20.	0.7	45
325	Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. Clinical and Experimental Nephrology, 2016, 20, 265-272.	0.7	22
326	Complement Deficiencies. , 2016, , 90-100.e4.		1
327	Biologic Therapies. , 2016, , 160-166.e4.		0

#	Article	IF	Citations
328	Immunosuppressive Medications. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 332-343.	2.2	184
329	An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatric Nephrology, 2016, 31, 15-39.	0.9	445
330	Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS). Immunobiology, 2016, 221, 715-718.	0.8	6
331	A national specialized service in England for atypical haemolytic uraemic syndromeâ€"the first yearâ€™s experience. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 27-33.	0.2	82
332	Eculizumab in Transplant-Associated Thrombotic Microangiopathy. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 175-180.	0.7	48
333	Indications of underdiagnosis of atypical haemolytic uraemic syndrome in a cohort referred to the Coagulation Unit in Malmo, Sweden, for analysis of ADAMTS13 2007â€"2012. Nephrology, 2017, 22, 555-561.	0.7	1
335	Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. Journal of Nephrology, 2017, 30, 127-134.	0.9	78
336	Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report. Transplantation Proceedings, 2017, 49, 188-192.	0.3	20
337	Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients. BMC Nephrology, 2017, 18, 6.	0.8	35
338	Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. CKJ: Clinical Kidney Journal, 2017, 10, sfw115.	1.4	56
339	Lifeâ€threatening pregnancyâ€associated atypical haemolytic uraemic syndrome and its response to eculizumab. Nephrology, 2017, 22, 32-35.	0.7	25
340	Haemolytic uraemic syndrome. Lancet, The, 2017, 390, 681-696.	6.3	397
341	Complementopathies. Blood Reviews, 2017, 31, 213-223.	2.8	86
342	Theranostic of biopharmaceuticals. , 2017, 175, 67-74.		5
343	Postpartum atypical hemolytic uremic syndrome with complement factor H mutation complicated by reversible cerebrovascular constriction syndrome successfully treated with eculizumab. Thrombosis Research, 2017, 151, 79-81.	0.8	7
344	Patients with hypertension-associated thromboticÂmicroangiopathy may present withÂcomplement abnormalities. Kidney International, 2017, 91, 1420-1425.	2.6	101
345	Subclinical atypical haemolytic uremic syndrome relapse following discontinuation of eculizumab. Nephrology, 2017, 22, 4-6.	0.7	2
346	Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatology International, 2017, 37, 1249-1255.	1.5	61

#	Article	IF	Citations
347	Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS. Pediatric Nephrology, 2017, 32, 1081-1087.	0.9	14
348	Absence of thrombocytopaenia and/or microangiopathic haemolytic anaemia does not reliably exclude recurrence of atypical haemolytic uraemic syndrome after kidney transplantation. Nephrology, 2017, 22, 28-31.	0.7	7
349	Paraprotein-associated thrombotic microangiopathy: expanding the spectrum of renal disease related to plasma cell dyscrasias. Kidney International, 2017, 91, 532-534.	2.6	5
350	Hemolytic Uremic Syndrome and Kidney Transplantation: A Case Series and Review of the Literature. Nephron, 2017, 136, 245-253.	0.9	11
351	Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?. CKJ: Clinical Kidney Journal, 2017, 10, 320-322.	1.4	10
353	Exudative retinal detachment. Survey of Ophthalmology, 2017, 62, 723-769.	1.7	49
354	Eculizumab for the treatment of hemolytic paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and refractory myasthenia gravis. Expert Opinion on Orphan Drugs, 2017, 5, 375-379.	0.5	1
355	Eculizumab cessation in atypical hemolytic uremic syndrome. Blood, 2017, 130, 368-372.	0.6	70
356	Expert Statements on the Standard of Care in Critically Ill Adult Patients With Atypical Hemolytic Uremic Syndrome. Chest, 2017, 152, 424-434.	0.4	37
357	Atypical hemolytic uremic syndrome. Renal Replacement Therapy, 2017, 3, .	0.3	6
358	Diagnostic approach to microangiopathic hemolytic disorders. International Journal of Laboratory Hematology, 2017, 39, 69-75.	0.7	22
359	An extremely rare splice site mutation in the gene encoding complement factor I in a patient with atypical hemolytic uremic syndrome. Journal of Clinical Apheresis, 2017, 32, 584-588.	0.7	1
360	Three Hypothetical Inflammation Pathobiology Phenotypes and Pediatric Sepsis-Induced Multiple Organ Failure Outcome*. Pediatric Critical Care Medicine, 2017, 18, 513-523.	0.2	81
361	Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome. Nephrology Dialysis Transplantation, 2017, 32, i115-i122.	0.4	20
362	Different types of glomerulonephritis associated with the dysregulation of the complement alternative pathway in 2 brothers. Medicine (United States), 2017, 96, e7144.	0.4	5
363	Two cases of atypical hemolytic uremic syndrome (aHUS) and eosinophilic granulomatosis with polyangiitis (EGPA): a possible relationship. CEN Case Reports, 2017, 6, 91-97.	0.5	5
364	Many drugs for many targets: novel treatments for complement-mediated glomerular disease. Nephrology Dialysis Transplantation, 2017, 32, i57-i64.	0.4	13
365	Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009â€"Results from a Randomized First-in-Human Phase 1 Trial. Transplantation, 2017, 101, 2410-2418.	0.5	26

#	Article	IF	Citations
366	Hemolytic Uremic Syndrome in Pregnancy and Postpartum. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1237-1247.	2.2	146
367	At the Cross Section of Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome: A Narrative Review of Differential Diagnostics and a Problematization of Nomenclature. Therapeutic Apheresis and Dialysis, 2017, 21, 304-319.	0.4	5
368	Kidney Diseases Associated With Alternative Complement Pathway Dysregulation and Potential Treatment Options. American Journal of the Medical Sciences, 2017, 354, 533-538.	0.4	8
369	Reversal of threatening blindness after initiation of eculizumab in Purtscher-like retinopathy secondary to atypical hemolytic uremic syndrome. International Ophthalmology, 2017, 38, 399-407.	0.6	14
370	Pathophysiology of Pediatric Multiple Organ Dysfunction Syndrome. Pediatric Critical Care Medicine, 2017, 18, S32-S45.	0.2	61
371	Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrology Dialysis Transplantation, 2017, 32, 466-474.	0.4	121
372	Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome. , 2017, , 851-871.		1
373	Anti-glomerular basement membrane glomerulonephritis with thrombotic microangiopathy: a case report. Immunologic Research, 2017, 65, 769-773.	1.3	4
374	Transplant-associated thrombotic microangiopathy: opening Pandoraâ€™s box. Bone Marrow Transplantation, 2017, 52, 1355-1360.	1.3	66
375	Discontinuation of Peritoneal Dialysis after Late Initiation of Eculizumab in a Case of Familial Atypical Hemolytic-Uremic Syndrome: A Case Report. Case Reports in Nephrology and Dialysis, 2017, 7, 18-25.	0.3	3
376	Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment. Clinical Pharmacology and Therapeutics, 2017, 102, 671-678.	2.3	38
377	Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nature Reviews Nephrology, 2017, 13, 359-367.	4.1	127
378	Syndromes of Thrombotic Microangiopathy. Medical Clinics of North America, 2017, 101, 395-415.	1.1	61
379	Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood, 2017, 129, 970-980.	0.6	119
380	Simple diagnosis and treatment algorithm for adult thrombotic microangiopathy. Transfusion and Apheresis Science, 2017, 56, 50-51.	0.5	3
381	After the Partyâ€™s Over. New England Journal of Medicine, 2017, 376, 74-80.	13.9	16
383	Complement Dysregulation and Disease: Insights from Contemporary Genetics. Annual Review of Pathology: Mechanisms of Disease, 2017, 12, 25-52.	9.6	70
384	Thrombotic Microangiopathy in Inverted Formin 2â€“Mediated Renal Disease. Journal of the American Society of Nephrology: JASN, 2017, 28, 1084-1091.	3.0	42

#	Article	IF	Citations
385	Acquired Bleeding Disorders. Hematology/Oncology Clinics of North America, 2017, 31, 1123-1145.	0.9	13
387	Complement System. , 2017, , 785-812.		0
388	Thrombotic Microangiopathy in a Patient Treated with Gemcitabine. Cancer Control, 2017, 24, 54-56.	0.7	5
389	Genome editing for scalable production of alloantigenâ€free lentiviral vectors for inÂvivo geneÂtherapy. EMBO Molecular Medicine, 2017, 9, 1558-1573.	3.3	41
390	Aortic Valve Replacement as a Trigger of Atypical Hemolytic Uremic Syndrome. Annals of Thoracic Surgery, 2017, 104, e255-e256.	0.7	6
391	Genetics of Immune-Mediated Glomerular Diseases: Focus on Complement. Seminars in Nephrology, 2017, 37, 447-463.	0.6	20
392	Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review. Clinical Rheumatology, 2017, 36, 2859-2867.	1.0	39
393	Signaling of the Complement Cleavage Product Anaphylatoxin C5a Through C5aR (CD88) Contributes to Pharmacological Hematopoietic Stem Cell Mobilization. Stem Cell Reviews and Reports, 2017, 13, 793-800.	5.6	18
394	Failure to Launch. JACC Basic To Translational Science, 2017, 2, 484-497.	1.9	44
395	Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence. Transplantation, 2017, 101, 2924-2930.	0.5	21
396	Thrombotic Microangiopathy: A Multidisciplinary TeamÂApproach. American Journal of Kidney Diseases, 2017, 70, 715-721.	2.1	20
397	A postpartum perfect storm. American Journal of Hematology, 2017, 92, 1105-1110.	2.0	1
398	Review: The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases. Arthritis and Rheumatology, 2017, 69, 2102-2113.	2.9	18
399	Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses. Molecular Immunology, 2017, 89, 111-114.	1.0	17
401	Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances. Nature Reviews Rheumatology, 2017, 13, 548-560.	3.5	153
402	Investigational drugs in systemic vasculitis. Expert Opinion on Investigational Drugs, 2017, 26, 1049-1061.	1.9	5
403	Quinine-Induced Thrombotic Microangiopathy: A Report ofÂ19ÂPatients. American Journal of Kidney Diseases, 2017, 70, 686-695.	2.1	30
406	The complement system as a potential therapeutic target in rheumatic disease. Nature Reviews Rheumatology, 2017, 13, 538-547.	3.5	147

#	Article	IF	Citations
407	Development and validation of an enzyme-linked immunosorbent assay to measure free eculizumab concentration in serum. Bioanalysis, 2017, 9, 1227-1235.	0.6	9
408	Meningococcal B Vaccine Failure With a Penicillin-Resistant Strain in a Young Adult on Long-Term Eculizumab. Pediatrics, 2017, 140, .	1.0	38
409	Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooledpost hocanalysis. Transplant International, 2017, 30, 1275-1283.	0.8	30
410	Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a lifeâ€saving treatment. Clinical Case Reports (discontinued), 2017, 5, 1926-1930.	0.2	37
411	Kidney Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Therapeutic Dilemma (or Not)?. American Journal of Kidney Diseases, 2017, 70, 754-757.	2.1	12
413	Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis. Journal of Immunology, 2017, 199, 1021-1040.	0.4	56
414	Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab. Clinical Immunology, 2017, 183, 1-7.	1.4	16
415	Pharmacologic Complement Inhibition in Clinical Transplantation. Current Transplantation Reports, 2017, 4, 91-100.	0.9	14
416	Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics. Journal of Thrombosis and Haemostasis, 2017, 15, 1889-1900.	1.9	112
417	Orphan drug policies and use in pediatric nephrology. Pediatric Nephrology, 2017, 32, 1-6.	0.9	22
418	Thrombotic microangiopathies: a general approach to diagnosis and management. Cmaj, 2017, 189, E153-E159.	0.9	96
419	Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy?. Bone Marrow Transplantation, 2017, 52, 352-356.	1.3	25
420	Haemolytic uraemic syndrome. Journal of Internal Medicine, 2017, 281, 123-148.	2.7	108
421	Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatric Nephrology, 2017, 32, 297-309.	0.9	48
422	Gemcitabine-Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine. Clinical Colorectal Cancer, 2017, 16, e119-e122.	1.0	14
423	Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. Journal of Nephrology, 2017, 30, 347-362.	0.9	64
424	Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. Journal of Thrombosis and Haemostasis, 2017, 15, 312-322.	1.9	362
425	An Update on the Use of Immunomodulators in Primary Immunodeficiencies. Clinical Reviews in Allergy and Immunology, 2017, 52, 287-303.	2.9	39

#	Article	IF	Citations
426	Complement Activation Induces Neutrophil Adhesion and Neutrophil-Platelet Aggregate Formation on Vascular Endothelial Cells. Kidney International Reports, 2017, 2, 66-75.	0.4	29
427	Efficacy of eculizumab in an adult patient with HIV-associated hemolytic uremic syndrome. Medicine (United States), 2017, 96, e9358.	0.4	7
428	A Case of Escherichia coli Hemolytic Uremic Syndrome in a 10-Year-Old Male With Severe Neurologic Involvement Successfully Treated With Eculizumab. Journal of Investigative Medicine High Impact Case Reports, 2017, 5, 232470961774114.	0.3	4
429	Risks of novel therapeutics: gonococcemia in an immune-suppressed patient receiving eculizumab. Cmaj, 2017, 189, E1558-E1560.	0.9	12
430	The role of complement inhibition in kidney transplantation. British Medical Bulletin, 2017, 124, 1-13.	2.7	9
431	Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. CKJ: Clinical Kidney Journal, 2017, 10, 600-624.	1.4	44
432	Complement activation: an atypical presentation of an atypical syndrome. BMJ Case Reports, 2017, 2017, bcr-2017-221798.	0.2	0
433	Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection. BMJ Case Reports, 2017, 2017, bcr-2016-219065.	0.2	6
434	Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Advances, 2017, 1, 1254-1258.	2.5	32
435	Thrombocytopenia in hospitalized patients: approach to the patient with thrombotic microangiopathy. Hematology American Society of Hematology Education Program, 2017, 2017, 651-659.	0.9	12
436	Complement in Kidney Transplantation. Frontiers in Medicine, 2017, 4, 66.	1.2	37
437	Complement in Non-Antibody-Mediated Kidney Diseases. Frontiers in Medicine, 2017, 4, 99.	1.2	11
438	Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation. Case Reports in Transplantation, 2017, 2017, 1-6.	0.1	8
439	Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice. PLoS ONE, 2017, 12, e0188155.	1.1	18
440	Early eculizumab use in atypical haemolytic uraemic syndrome in a Jehovahâ€™s Witness refusing blood products. Oxford Medical Case Reports, 2017, 2017, omx025.	0.2	1
441	Differential diagnosis of thrombotic microangiopathy in nephrology. BMC Nephrology, 2017, 18, 324.	0.8	3
442	Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report. Journal of Medical Case Reports, 2017, 11, 209.	0.4	14
443	Microangiopathic Hemolytic Anemia. , 0, , 113-121.		0

#	Article	IF	Citations
444	Novel complement factor H gene mutation causing atypical haemolytic uraemic syndrome: early Eculizumab prevents acute dialysis. CKJ: Clinical Kidney Journal, 2017, 10, 263-265.	1.4	0
445	Enterococcus raffinosus infection with atypical hemolytic uremic syndrome in a multiple myeloma patient after autologous stem cell transplant. Hematology Reports, 2017, 9, 7094.	0.3	4
446	Atypical Hemolytic Uremic Syndrome: A Brief Review. Hematology Reports, 2017, 9, 7053.	0.3	49
447	Long-term Eculizumab Treatment Contributes to Recovery from End-stage Renal Disease Caused by Atypical Hemolytic Uremic Syndrome. Internal Medicine, 2017, 56, 1085-1088.	0.3	4
448	A Patient with Hemolytic Uremic Syndrome and Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 933-936.	2.2	1
449	C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome: Two Important Manifestations of Complement System Dysfunction. Case Reports in Nephrology and Dialysis, 2018, 8, 25-34.	0.3	4
450	Safety and efficacy of eculizumab in Guillain-BarrÃ© syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurology, The, 2018, 17, 519-529.	4.9	111
451	High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma. Bone Marrow Transplantation, 2018, 53, 1311-1318.	1.3	41
452	Anticomplement Treatment in Atypical and Typical Hemolytic Uremic Syndrome. Seminars in Hematology, 2018, 55, 150-158.	1.8	39
453	Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report. Transplantation Proceedings, 2018, 50, 967-970.	0.3	3
454	Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Internal Medicine Journal, 2018, 48, 624-636.	0.5	26
455	A 22â€Yearâ€Old Woman With Systemic Lupus Erythematosus Presents With Two Damaged Kidneys, One Seizure, No Platelets, and Many Possible Diagnoses. Arthritis Care and Research, 2018, 70, 1686-1693.	1.5	1
456	Thrombotic microangiopathies of pregnancy: Differential diagnosis. Pregnancy Hypertension, 2018, 12, 29-34.	0.6	78
457	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Clinical Microbiology and Infection, 2018, 24, S21-S40.	2.8	167
458	Mechanisms of Complement-Mediated Damage in Hematological Disorders. Seminars in Hematology, 2018, 55, 118-123.	1.8	8
459	Evaluation of health-related quality of life in hemolytic uraemic syndrome patients treated with eculizumab: a systematic evaluation on basis of EMPRO. Renal Failure, 2018, 40, 107-118.	0.8	8
460	C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab. Nephrology Dialysis Transplantation, 2018, 33, 2260-2265.	0.4	17
461	Carboxypeptidase B2 and N play different roles in regulation of activated complements C3a and C5a in mice. Journal of Thrombosis and Haemostasis, 2018, 16, 991-1002.	1.9	16

#	Article	IF	Citations
462	The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential. Journal of the American Society of Nephrology: JASN, 2018, 29, 1141-1153.	3.0	28
463	Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Nephrology, 2018, 23, 507-517.	0.7	21
464	Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy. American Journal of Kidney Diseases, 2018, 72, 84-92.	2.1	94
465	Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Journal of Thrombosis and Haemostasis, 2018, 16, 618-629.	1.9	41
466	Haemostasis and innate immunity â€“ a complementary relationship. British Journal of Haematology, 2018, 180, 782-798.	1.2	120
467	Maternal and Fetal Outcomes of Pregnancies in Women with Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2018, 29, 1020-1029.	3.0	56
468	Glucose-6-Phosphate Dehydrogenase Deficiency Mimicking Atypical Hemolytic Uremic Syndrome. American Journal of Kidney Diseases, 2018, 71, 287-290.	2.1	4
469	Atypical Presentation of Pregnancy-Related Hemolytic Uremic Syndrome. American Journal of Kidney Diseases, 2018, 72, 451-456.	2.1	9
471	Case Series of 3 Patients Diagnosed With Atypical Hemolytic Uremic Syndrome Successfully Treated With Steroids, Plasmapheresis, and Rituximab. Canadian Journal of Kidney Health and Disease, 2018, 5, 205435811774726.	0.6	0
472	A Rare Case of Lupus Nephritis Presenting as Thrombotic Microangiopathy with Diffuse Pseudotubulization Possibly Caused by Atypical Hemolytic Uremic Syndrome. Internal Medicine, 2018, 57, 1617-1623.	0.3	8
473	SÃndrome hemolÃtico urÃ©mico: estado actual. Medicina ClÃnica, 2018, 151, 329-335.	0.3	9
474	Use of eculizumab in pregnancy-associated atypical hemolytic uremic syndrome. Case Reports in Perinatal Medicine, 2018, 7, .	0.1	1
475	Pathogenesis and treatment of ANCA-associated vasculitisâ€”a role for complement. Pediatric Nephrology, 2018, 33, 1-11.	0.9	19
477	A case of atypical hemolytic uremic syndrome in a second renal transplant. Journal of Nephrology, 2018, 31, 165-172.	0.9	2
478	Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients. Nephrology, 2018, 23, 539-545.	0.7	7
479	Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrology Dialysis Transplantation, 2018, 33, 635-645.	0.4	36
480	Thrombotic Microangiopathy and the Kidney. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 300-317.	2.2	234
481	Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update. Pediatric Nephrology, 2018, 33, 457-461.	0.9	40

#	Article	IF	Citations
482	Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome. Acta Clinica Belgica, 2018, 73, 80-89.	0.5	12
483	Thrombotic microangiopathy following haematopoietic stem cell transplant. Pediatric Nephrology, 2018, 33, 1489-1500.	0.9	29
484	Effective treatment of chemotherapy induced atypical Haemolytic Uraemic Syndrome: a case series of 7 treated patients. British Journal of Haematology, 2018, 183, 136-139.	1.2	13
485	A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney International, 2018, 93, 450-459.	2.6	100
486	C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti-myeloperoxidase glomerulonephritis. Kidney International, 2018, 93, 615-625.	2.6	64
487	Atypical Hemolytic Uremic Syndrome: A Metaâ€Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens. Therapeutic Apheresis and Dialysis, 2018, 22, 178-188.	0.4	27
488	De novo thrombotic microangiopathy after kidney transplantation. Transplantation Reviews, 2018, 32, 58-68.	1.2	59
489	Advances in our understanding of the pathogenesis of hemolytic uremic syndromes. American Journal of Physiology - Renal Physiology, 2018, 314, F454-F461.	1.3	17
490	Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight, 2018, 3, .	2.3	65
491	InvestigaciÃ³n multidisciplinar y traslacional en enfermedades raras. Arbor, 2018, 194, 468.	0.1	0
492	Complement-mediated renal diseases after kidney transplantation - current diagnostic and therapeutic options in de novo and recurrent diseases. World Journal of Transplantation, 2018, 8, 203-219.	0.6	3
493	Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody. PLoS ONE, 2018, 13, e0209509.	1.1	38
494	Clinical and Complement Long-Term Follow-Up of a Pediatric Patient with C3 Mutation-Related Atypical Hemolytic Uremic Syndrome. Case Reports in Nephrology, 2018, 2018, 1-4.	0.2	0
495	Serum complement factor I is associated with disease activity of systemic lupus erythematosus. Oncotarget, 2018, 9, 8502-8511.	0.8	14
496	Hemostatic Abnormalities in the Critically Ill. , 2018, , 17-39.		0
497	An adult case of atypical hemolytic uremic syndrome presented with posterior reversible encephalopathy syndrome: Successful response to late-onset eculizumab treatment. Hematology Reports, 2018, 10, 7553.	0.3	6
498	Severe refractory idiopathic warm autoimmune haemolytic anaemia responsive to complement inhibition with eculizumab. BMJ Case Reports, 2018, 11, e226429.	0.2	11
499	Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition. Hemoglobin, 2018, 42, 339-341.	0.4	22

#	Article	IF	Citations
500	Terminal Complement Activation in Preeclampsia. Obstetrics and Gynecology, 2018, 132, 1477-1485.	1.2	35
501	A rare case of Alport syndrome, atypical hemolytic uremic syndrome and Pauci-immune crescentic glomerulonephritis. BMC Nephrology, 2018, 19, 355.	0.8	6
502	Prognosis and future developments in vasculitis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 148-165.	1.4	18
503	Overview of Pathophysiology of Acute Kidney Injury: Human Evidence, Mechanisms, Pathological Correlations and Biomarkers and Animal Models. , 2018, , 45-67.		3
504	Where are we with haemolytic uremic syndrome?. Medicina ClÃnica (English Edition), 2018, 151, 329-335.	0.1	0
505	Impact of a multidisciplinary team for the management of thrombotic microangiopathy. PLoS ONE, 2018, 13, e0206558.	1.1	8
506	Therapeutic Apheresis for Hematologic Emergencies. , 2018, , 341-361.		0
508	Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome. Mayo Clinic Proceedings, 2018, 93, 1351-1362.	1.4	17
509	Complement Biomarkers of Hemolytic Uremic Syndromeâ€"If Not One Thing, Maybe Another. Mayo Clinic Proceedings, 2018, 93, 1337-1339.	1.4	2
510	Genetic Analysis of 400 Patients Refines Understanding and Implicates a New Gene in Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2018, 29, 2809-2819.	3.0	50
511	Eculizumab and thrombotic microangiopathy after hematopoietic stem cell transplantation: A report on its efficacy and safety in two pediatric patients. Archives De Pediatrie, 2018, 25, 485-488.	0.4	4
512	Early Differentiation of Shiga Toxinâ€"Associated Hemolytic Uremic Syndrome in Critically Ill Adults With Thrombotic Microangiopathy Syndromes. Critical Care Medicine, 2018, 46, e904-e911.	0.4	8
513	Microangiopathic Hemolytic Anemia in Pregnancy. Transfusion Medicine Reviews, 2018, 32, 230-236.	0.9	32
514	Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury. American Journal of Nephrology, 2018, 48, 225-233.	1.4	21
516	Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab. Pediatric Nephrology, 2018, 33, 2371-2381.	0.9	14
517	Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD. Blood Advances, 2018, 2, 2619-2628.	2.5	49
518	Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Advances, 2018, 2, 2543-2549.	2.5	74
519	Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria. Hematology American Society of Hematology Education Program, 2018, 2018, 371-376.	0.9	15

#	Article	IF	Citations
520	Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Advances, 2018, 2, 2090-2094.	2.5	70
521	Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion. Blood Advances, 2018, 2, 3443-3446.	2.5	34
522	Clinical Manifestation of Patients With Atypical Hemolytic Uremic Syndrome With the C3 p.I1157T Variation in the Kinki Region of Japan. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 1301-1307.	0.7	12
523	Atypical Hemolytic Uremic Syndrome. Pediatric Clinics of North America, 2018, 65, 509-525.	0.9	28
525	De Novo Atypical Haemolytic Uremic Syndrome after Kidney Transplantation. Case Reports in Nephrology, 2018, 2018, 1-4.	0.2	2
526	Evaluation of Hemolysis as a Severe Feature of Preeclampsia. Hypertension, 2018, 72, 460-465.	1.3	23
527	The impact of eculizumab on routine complement assays. Journal of Immunological Methods, 2018, 460, 63-71.	0.6	22
528	The Differential Diagnosis and Treatment of Thrombotic Microangiopathies. Deutsches Ärzteblatt International, 2018, 115, 327-334.	0.6	39
529	Clinical Relapses of Atypical HUS on Eculizumab: Clinical Gap for Monitoring and Individualised Therapy. Case Reports in Nephrology, 2018, 2018, 1-4.	0.2	1
530	Description of the Use of Plasma Exchange in Dogs With Cutaneous and Renal Glomerular Vasculopathy. Frontiers in Veterinary Science, 2018, 5, 161.	0.9	11
532	Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management. Journal of Immunological Methods, 2018, 461, 15-22.	0.6	34
535	Complement and Immunoglobulin Biology Leading to Clinical Translation. , 2018, , 261-284.e6.		0
536	Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases. Frontiers in Immunology, 2018, 9, 612.	2.2	30
537	Modeling Hemolytic-Uremic Syndrome: In-Depth Characterization of Distinct Murine Models Reflecting Different Features of Human Disease. Frontiers in Immunology, 2018, 9, 1459.	2.2	22
538	C3 glomerulonephritis and thrombotic microangiopathy of renal allograft after pulmonary infection in a male with concomitant two complement factor I gene variations: a case report. BMC Nephrology, 2018, 19, 148.	0.8	7
539	Insights into pregnancy associated and atypical hemolytic uremic syndrome. Obstetric Medicine, 2018, 11, 137-140.	0.5	1
540	Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thrombosis Journal, 2018, 16, 14.	0.9	75
541	Atypical haemolytic and uraemic syndrome: how can we protect the kidneys?. Nephrology Dialysis Transplantation, 2018, 33, 1708-1711.	0.4	0

#	Article	IF	Citations
542	Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab. Nephrology Dialysis Transplantation, 2018, 35, 298-303.	0.4	17
544	Treating C3 glomerulopathy with eculizumab. BMC Nephrology, 2018, 19, 7.	0.8	46
545	Validation of PLASMIC score and follow-up data in a cohort of patients with suspected microangiopathies from Southern Italy. Journal of Thrombosis and Thrombolysis, 2018, 46, 174-179.	1.0	19
546	Hemolytic Uremic Syndrome. , 2018, , 129-144.		24
547	How to mitigate the risk of inducing transfusion-associated adverse reactions. Transfusion Clinique Et Biologique, 2018, 25, 262-268.	0.2	18
548	When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies. American Journal of Nephrology, 2018, 48, 96-107.	1.4	45
549	Atypical Haemolytic Uraemic Syndrome Associated with Clostridium difficile Infection Successfully Treated with Eculizumab. Case Reports in Nephrology, 2018, 2018, 1-4.	0.2	6
550	Developments in anti-complement therapy; from disease to clinical trial. Molecular Immunology, 2018, 102, 89-119.	1.0	72
551	C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension. Journal of the American Society of Nephrology: JASN, 2018, 29, 2234-2243.	3.0	73
552	Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia. Journal of the American Society of Nephrology: JASN, 2018, 29, 1928-1937.	3.0	29
553	Carboxypeptidase B2 and carboxypeptidase N in the crosstalk between coagulation, thrombosis, inflammation, and innate immunity. Journal of Thrombosis and Haemostasis, 2018, 16, 1474-1486.	1.9	37
554	Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype andÂoutcome. Kidney International, 2018, 94, 408-418.	2.6	117
555	Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study. CKJ: Clinical Kidney Journal, 2019, 12, 196-205.	1.4	16
556	Atypical hemolytic uremic syndrome: a syndrome in need of clarity. CKJ: Clinical Kidney Journal, 2019, 12, 338-347.	1.4	15
557	Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome. Pediatric Nephrology, 2019, 34, 1485-1492.	0.9	33
558	Safety and effectiveness of eculizumab for pediatric patients with atypical hemolyticâ€“uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clinical and Experimental Nephrology, 2019, 23, 112-121.	0.7	31
559	Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab. Journal of Oncology Pharmacy Practice, 2019, 25, 1011-1015.	0.5	16
560	Safety and effectiveness of eculizumab for adult patients with atypical hemolyticâ€“uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clinical and Experimental Nephrology, 2019, 23, 65-75.	0.7	15

#	Article	IF	Citations
561	Atypical Hemolytic Uremic Syndrome: Beyond Hemolysis and Uremia. American Journal of Medicine, 2019, 132, 161-167.	0.6	16
562	The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?. Pediatric Nephrology, 2019, 34, 1349-1367.	0.9	15
563	Steroid Responsive Atypical Hemolytic Uremic Syndrome Triggered by Influenza B Infection. Journal of Pediatric Hematology/Oncology, 2019, 41, e63-e67.	0.3	7
564	Complement Activation in Progression of Chronic Kidney Disease. Advances in Experimental Medicine and Biology, 2019, 1165, 423-441.	0.8	19
565	Neutrophil Extracellular Trap Formation: Physiology, Pathology, and Pharmacology. Biomolecules, 2019, 9, 365.	1.8	151
566	Eculizumab hypersensitivity and desensitization in a toddler with atypical hemolytic uremic syndrome. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2409-2410.	2.0	4
567	Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. Journal of the Neurological Sciences, 2019, 407, 116419.	0.3	18
569	Targeting the complement system in bacterial meningitis. Brain, 2019, 142, 3325-3337.	3.7	36
571	Clinical promise of next-generation complement therapeutics. Nature Reviews Drug Discovery, 2019, 18, 707-729.	21.5	253
573	A review of thrombotic microangiopathies in multiple myeloma. Leukemia Research, 2019, 85, 106195.	0.4	17
574	Deterioration in Clinical Status Is Not Enough to Suspend Eculizumab: A Genetic Complement-Mediated Atypical Hemolytic Uremic Syndrome Case Report. Case Reports in Nephrology, 2019, 2019, 1-5.	0.2	1
575	Atypical hemolytic uremic syndrome in a patient with protein-losing enteropathy. Journal of International Medical Research, 2019, 47, 4027-4032.	0.4	6
576	Hemolytic Uremic Syndrome. , 2019, , 294-301.e2.		0
577	Management of Select Thrombocytopenias. AACN Advanced Critical Care, 2019, 30, 165-180.	0.6	1
581	Therapeutic Modulation of the Complement System in Kidney Transplantation: Clinical Indications and Emerging Drug Leads. Frontiers in Immunology, 2019, 10, 2306.	2.2	18
582	Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics. Transfusion Medicine Reviews, 2019, 33, 256-265.	0.9	46
583	The PLASMIC Score May Be Useful in the Early Diagnosis of Complement-Mediated Thrombotic Microangiopathy via Early Exclusion of Thrombotic Thrombocytopenic Purpura. Case Reports in Medicine, 2019, 2019, 1-3.	0.3	3
584	Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura. Blood Research, 2019, 54, 218-228.	0.5	9

#	Article	IF	Citations
585	The role of Complement in Post-Transfusion Hemolysis and Hyperhemolysis Reaction. Transfusion Medicine Reviews, 2019, 33, 225-230.	0.9	16
587	Renal Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Single Center Experience. Transplantation Proceedings, 2019, 51, 2295-2297.	0.3	3
588	Mechanisms of haemolysis-induced kidney injury. Nature Reviews Nephrology, 2019, 15, 671-692.	4.1	97
589	Complement Inhibitors in Clinical Trials for Glomerular Diseases. Frontiers in Immunology, 2019, 10, 2166.	2.2	86
590	Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature. Pediatric Nephrology, 2019, 34, 2601-2604.	0.9	4
591	Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry. Kidney International Reports, 2019, 4, 1568-1576.	0.4	50
592	Therapeutic apheresis during pregnancy: A single center experience. Transfusion and Apheresis Science, 2019, 58, 652-658.	0.5	23
593	63-Year-Old Woman With Abdominal Pain and Thrombocytopenia. Mayo Clinic Proceedings, 2019, 94, 2122-2126.	1.4	0
594	Optimal management of atypical hemolytic uremic disease: challenges and solutions . International Journal of Nephrology and Renovascular Disease, 2019, Volume 12, 183-204.	0.8	23
595	Complement inhibitors are useful in secondary hemolytic uremic syndromes. Kidney International, 2019, 96, 826-829.	2.6	11
596	Classifications of scleroderma renal crisis and reconsideration of its pathophysiology. Rheumatology, 2019, 58, 2099-2106.	0.9	21
597	Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)â€"a question to be addressed in a scientific way. Pediatric Nephrology, 2019, 34, 943-949.	0.9	24
599	Complement Gene Variants and Shiga Toxinâ€"Producing Escherichia coliâ€"Associated Hemolytic Uremic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 364-377.	2.2	33
600	Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene. CEN Case Reports, 2019, 8, 139-143.	0.5	3
601	Eculizumab deposits in vessel walls in thrombotic microangiopathy. Kidney International, 2019, 96, 761-768.	2.6	12
602	Invasive meningococcal disease in patients with complement deficiencies: a case series (2008â€"2017). BMC Infectious Diseases, 2019, 19, 522.	1.3	34
603	Biopsyâ€proven thrombotic microangiopathy without schistocytosis on peripheral blood smear: A cautionary tale. American Journal of Hematology, 2019, 94, E234-E237.	2.0	10
604	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice â€" Evidenceâ€Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. Journal of Clinical Apheresis, 2019, 34, 171-354.	0.7	1,263

#	Article	IF	Citations
605	Membraneâ€filtration based plasma exchanges for atypical hemolytic uremic syndrome: Audit of efficacy and safety. Journal of Clinical Apheresis, 2019, 34, 555-562.	0.7	9
606	Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome. Kidney International, 2019, 96, 995-1004.	2.6	52
607	Deleterious Impact of a Novel CFH Splice Site Variant in Atypical Hemolytic Uremic Syndrome. Frontiers in Genetics, 2019, 10, 465.	1.1	3
608	Secondary atypical hemolytic uremic syndromes in the era of complement blockade. Kidney International, 2019, 95, 1298-1300.	2.6	12
609	Sepsis-associated disseminated intravascular coagulation and its differential diagnoses. Journal of Intensive Care, 2019, 7, 32.	1.3	42
610	Therapeutic plasma exchange â€“ A brief review of indications, urgency, schedule, and technical aspects. Transfusion and Apheresis Science, 2019, 58, 237-246.	0.5	22
611	Postpartum care of women with renal disease. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2019, 57, 89-105.	1.4	8
612	Pregnancy in a Kidney Transplant Woman Under Treatment With Eculizumab forÂAtypical Hemolytic Uremic Syndrome: IsÂIt Safe?. Kidney International Reports, 2019, 4, 733-739.	0.4	10
613	An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. CKJ: Clinical Kidney Journal, 2019, 12, 333-337.	1.4	35
614	Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies. American Journal of Transplantation, 2019, 19, 2865-2875.	2.6	67
615	Therapeutic plasma exchange in nephrology. Where it applies?. Transfusion and Apheresis Science, 2019, 58, 262-265.	0.5	7
616	Hemolytic uremic syndrome in a developing country: Consensus guidelines. Pediatric Nephrology, 2019, 34, 1465-1482.	0.9	47
617	Meta-analysis for a therapeutic target involved in the activation of the genes associated with C3 glomerulopathy. , 2019, , .		2
618	Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial. American Journal of Transplantation, 2019, 19, 2876-2888.	2.6	95
619	Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. Frontiers in Immunology, 2019, 10, 337.	2.2	69
620	Circulating Heme Oxygenase-1 and Complement Activation in Transplant-Associated Thrombotic Microangiopathy. Biology of Blood and Marrow Transplantation, 2019, 25, 1486-1491.	2.0	11
621	An ExÂVivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. American Journal of Kidney Diseases, 2019, 74, 56-72.	2.1	71
622	Atypical and secondary hemolytic uremic syndromes have a distinct presentation andÂnoÂcommon genetic risk factors. Kidney International, 2019, 95, 1443-1452.	2.6	74

#	Article	IF	Citations
623	Seizure as the Presenting Symptom for Atypical Hemolytic Uremic Syndrome. Journal of Emergency Medicine, 2019, 56, 441-443.	0.3	2
624	Long-term Use ofÂEculizumab in Kidney Transplant Recipients. Kidney International Reports, 2019, 4, 370-371.	0.4	2
625	Atypical haemolytic uraemic syndrome in the eculizumab era: presentation, response to treatment and evaluation of an eculizumab withdrawal strategy. British Journal of Haematology, 2019, 186, 113-124.	1.2	6
626	Preeclampsia. Circulation Research, 2019, 124, 1094-1112.	2.0	1,019
627	Outcome of kidney transplantation from young pediatric donors (aged less than 6 years) to young size-matched recipients. Journal of Pediatric Urology, 2019, 15, 213-220.	0.6	8
628	Thrombocytopenic emergencies. British Journal of Hospital Medicine (London, England: 2005), 2019, 80, C18-C21.	0.2	0
629	Thrombotic Thrombocytopenic Purpura and Hemolytic-Uremic Syndromes. , 2019, , 769-794.		0
630	Thrombocytopenia in Pregnancy. , 2019, , 795-812.		1
631	Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions. Transfusion Clinique Et Biologique, 2019, 26, 116-124.	0.2	32
632	Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrology, 2019, 20, 125.	0.8	77
634	The Complement System. , 2019, , 65-79.		0
635	Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome. Haematologica, 2019, 104, 2501-2511.	1.7	40
636	The Role of Complement in the Pathogenesis of HUS and the TMA Spectrum Disorders. Current Pediatrics Reports, 2019, 7, 1-11.	1.7	3
637	Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10â€year pharmacovigilance analysis. British Journal of Haematology, 2019, 185, 297-310.	1.2	148
638	Eculizumab in paediatric atypical haemolytic uraemic syndrome: Lessons learned from a singleâ€centre experience in the United Arab Emirates. Journal of Paediatrics and Child Health, 2019, 55, 1237-1240.	0.4	5
639	Hematopoietic Stem Cell Transplant and Cellular Therapy. , 2019, , 109-158.		1
640	Hemolytic Uremic Syndrome, Genetic. , 2019, , 667-679.		0
641	Integration with Kidney Disease Improving Global Outcomes (KDIGO). , 2019, , 87-95.		1

#	Article	IF	Citations
642	Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clinical Pharmacokinetics, 2019, 58, 859-874.	1.6	82
644	A case of Moyamoya disease complicated by aHUS in a patient with a history of marginal zone B-cell lymphoma: lightning strikes thrice?. BMJ Case Reports, 2019, 12, e229194.	0.2	0
645	VarÃ³n de 73 aÃ±os con diarrea sanguinolenta y fracaso renal agudo grave. Medicine, 2019, 12, 4864.e1-4864.e3.	0.0	0
646	Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2019, 30, 2449-2463.	3.0	81
647	Variability in management and outcomes of therapy with eculizumab in atypical hemolytic uremic syndrome. Expert Opinion on Orphan Drugs, 2019, 7, 525-533.	0.5	0
648	Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature. ESMO Open, 2019, 4, e000551.	2.0	15
649	Indications of plasma exchanges in combination with intravenous immunoglobulins or therapeutic monoclonal antibodies. How to combine them?. Presse Medicale, 2019, 48, 354-359.	0.8	3
650	Complement and Complement Targeting Therapies in Glomerular Diseases. International Journal of Molecular Sciences, 2019, 20, 6336.	1.8	18
651	Hemolysis Derived Products Toxicity and Endothelium: Model of the Second Hit. Toxins, 2019, 11, 660.	1.5	55
652	Pharmacokinetics and Pharmacodynamics Estimation of Eculizumab in a 2-Year-Old Girl With Atypical Hemolytic Uremic Syndrome: A Case Report With 4-Year Follow-Up. Frontiers in Pediatrics, 2019, 7, 519.	0.9	3
653	Eculizumab Is Safe and Effective as a Longâ€term Treatment for Proteinâ€losing Enteropathy Due to CD55 Deficiency. Journal of Pediatric Gastroenterology and Nutrition, 2019, 68, 325-333.	0.9	19
654	Complement, infection, and autoimmunity. Current Opinion in Rheumatology, 2019, 31, 532-541.	2.0	76
655	Drugâ€induced Thrombotic Microangiopathy During Maintenance Treatment in a Patient With Multiple Myeloma. HemaSphere, 2019, 3, e192.	1.2	6
656	Emerging immunotherapies for autoimmune kidney disease. Human Vaccines and Immunotherapeutics, 2019, 15, 876-890.	1.4	3
657	Thrombotic microangiopathy in a patient with eosinophilic granulomatosis with polyangiitis: case-based review. Rheumatology International, 2019, 39, 359-365.	1.5	5
658	Differential diagnoses for sepsisâ€induced disseminated intravascular coagulation: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2019, 17, 415-419.	1.9	50
659	Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatric Nephrology, 2019, 34, 2261-2277.	0.9	60
660	Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort. British Journal of Clinical Pharmacology, 2019, 85, 403-412.	1.1	39

#	Article	IF	Citations
661	Pathogenesis of Atypical Hemolytic Uremic Syndrome. Journal of Atherosclerosis and Thrombosis, 2019, 26, 99-110.	0.9	53
662	Hemolytic Uremic Syndrome. Pediatric Clinics of North America, 2019, 66, 235-246.	0.9	77
663	Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?. Bone Marrow Transplantation, 2019, 54, 913-916.	1.3	2
664	Improvement of pharmacokinetic properties of therapeutic antibodies by antibody engineering. Drug Metabolism and Pharmacokinetics, 2019, 34, 25-41.	1.1	21
665	C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro. Journal of Immunology, 2019, 202, 1200-1209.	0.4	20
666	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 281-295.	2.6	135
667	Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome. Kidney International Reports, 2019, 4, 434-446.	0.4	59
668	Glyco-iELISA: a highly sensitive and unambiguous serological method to diagnose STEC-HUS caused by serotype O157. Pediatric Nephrology, 2019, 34, 631-639.	0.9	7
669	Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Seminars in Arthritis and Rheumatism, 2019, 49, 74-83.	1.6	97
670	Acquired Thrombocytopenia. , 2019, , 135-148.		0
671	Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitorâ€“experienced adult patients with PNH: the 302 study. Blood, 2019, 133, 540-549.	0.6	239
672	Atypical Hemolyticâ€Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Therapeutic Apheresis and Dialysis, 2019, 23, 4-21.	0.4	95
673	Complement-Mediated Coagulation Disorders. , 2019, , 473-490.		0
674	Successful treatment of a Streptococcus pneumoniae-associated haemolytic uraemic syndrome by eculizumab. CKJ: Clinical Kidney Journal, 2019, 12, 106-109.	1.4	12
675	Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study. Nephrology Dialysis Transplantation, 2020, 35, 2147-2153.	0.4	15
676	Approach to the Patient with Chronic Glomerular Disease. , 2020, , 721-736.		0
677	Atypical Hemolytic Uremic Syndrome After Kidney Transplantation: Lessons Learned From the Good, the Bad, and the Ugly. A Case Series With Literature Review. Transplantation Proceedings, 2020, 52, 146-152.	0.3	8
678	C3 glomerulopathy: experience of a pediatric nephrology center. Acta Clinica Belgica, 2021, 76, 253-257.	0.5	3

#	Article	IF	Citations
679	Role of the Complement Pathway in Inflammatory Skin Diseases: A Focus on Hidradenitis Suppurativa. Journal of Investigative Dermatology, 2020, 140, 531-536.e1.	0.3	28
680	Complement C5 Contributes to Brain Injury After Subarachnoid Hemorrhage. Translational Stroke Research, 2020, 11, 678-688.	2.3	24
681	Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome. Pharmacoeconomics, 2020, 38, 307-313.	1.7	11
682	Pregnancy-Associated Atypical Hemolytic Uremic Syndrome. Obstetrics and Gynecology, 2020, 135, 46-58.	1.2	41
684	Antilymphocyte Globulin, Monoclonal Antibodies, and Fusion Proteins. , 2020, , 283-312.		0
685	Diagnostic and Risk Factors for Complement Defects in Hypertensive Emergency and Thrombotic Microangiopathy. Hypertension, 2020, 75, 422-430.	1.3	46
686	Renal microvascular lesions in lupus nephritis. Renal Failure, 2020, 42, 19-29.	0.8	29
687	Complement 5 Inhibition Ameliorates Hepatic Ischemia/reperfusion Injury in Mice, Dominantly via the C5a-mediated Cascade. Transplantation, 2020, 104, 2065-2077.	0.5	14
688	Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome. American Journal of Obstetrics and Gynecology, 2022, 226, S1059-S1070.	0.7	29
689	A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome. Journal of Medical Economics, 2020, 23, 1503-1515.	1.0	20
690	International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13. International Journal of Laboratory Hematology, 2020, 42, 685-696.	0.7	26
691	Shiga Toxin Selectively Upregulates Expression of Syndecan-4 and Adhesion Molecule ICAM-1 in Human Glomerular Microvascular Endothelium. Toxins, 2020, 12, 435.	1.5	3
692	Eculizumabâ€induced late erythroid maturation arrest: a case report. British Journal of Haematology, 2020, 191, 120-122.	1.2	2
693	ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2486-2495.	1.9	142
694	Recurrent Complement-Mediated Thrombotic Microangiopathy in a Patient with Systemic Lupus Erythematosus. HSS Journal, 2020, 16, 507-514.	0.7	0
695	Plasma exchange and thrombotic microangiopathies: From pathophysiology to clinical practice. Transfusion and Apheresis Science, 2020, 59, 102990.	0.5	5
696	Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study. Kidney and Blood Pressure Research, 2020, 45, 939-954.	0.9	4
698	Peri- and Post-operative Evaluation and Management of Atypical Hemolytic Uremic Syndrome (aHUS) in Kidney Transplantation. Advances in Chronic Kidney Disease, 2020, 27, 128-137.	0.6	4

#	Article	IF	Citations
699	Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study. EClinicalMedicine, 2020, 28, 100590.	3.2	129
700	Ex vivo assays to detect complement activation in complementopathies. Clinical Immunology, 2020, 221, 108616.	1.4	7
701	MED-TMA: A clinical decision support tool for differential diagnosis of TMA with enhanced accuracy using an ensemble method. Thrombosis Research, 2020, 193, 154-159.	0.8	3
702	From COVID-19 to clot: the involvement of the complement system. Journal of Biomolecular Structure and Dynamics, 2022, 40, 1909-1914.	2.0	31
703	Podocyte Involvement in Renal Thrombotic Microangiopathy: A Clinicopathological Study. American Journal of Nephrology, 2020, 51, 752-760.	1.4	14
704	Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era. Nephron, 2020, 144, 537-549.	0.9	26
705	The Inhibition of Complement System in Formal and Emerging Indications: Results from Parallel One-Stage Pairwise and Network Meta-Analyses of Clinical Trials and Real-Life Data Studies. Biomedicines, 2020, 8, 355.	1.4	10
706	Diagnostic dilemma in postpartum associated hemolytic uremic syndrome in a 38th week pregnant 31-year-old Congolese: a case report. BMC Pregnancy and Childbirth, 2020, 20, 495.	0.9	0
707	Severe Acute Kidney Injury in Cardiovascular Surgery: Thrombotic Microangiopathy as a Differential Diagnosis to Ischemia Reperfusion Injury. A Retrospective Study. Journal of Clinical Medicine, 2020, 9, 2900.	1.0	3
708	Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives. Frontiers in Pharmacology, 2020, 11, 572870.	1.6	72
709	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood, 2020, 136, 2103-2117.	0.6	82
710	The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naÃ¯ve to complement inhibitor treatment. Kidney International, 2021, 100, 225-237.	2.6	43
711	Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study. Frontiers in Neurology, 2020, 11, 556104.	1.1	17
712	Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Frontiers in Immunology, 2020, 11, 599417.	2.2	31
714	Hemolytic Uremic Syndrome. Current Treatment Options in Pediatrics, 2020, 6, 252-262.	0.2	3
715	Complement-mediated kidney diseases. Molecular Immunology, 2020, 128, 175-187.	1.0	31
716	Baseline characteristics of patients with atypical haemolytic uraemic syndrome (aHUS): The Australian cohort in a global aHUS registry. Nephrology, 2020, 25, 683-690.	0.7	6
717	Is ravulizumab the new treatment of choice for atypical hemolytic uremic syndrome (aHUS)?. Kidney International, 2020, 97, 1106-1108.	2.6	8

#	Article	IF	Citations
718	Atypical haemolytic uraemic syndrome: a case report of a rare cause of reversible cardiomyopathy. European Heart Journal - Case Reports, 2020, 4, 1-6.	0.3	4
719	The natural course of pregnancies in women with primary atypical haemolytic uraemic syndrome and asymptomatic relatives. British Journal of Haematology, 2020, 190, 442-449.	1.2	12
720	The case of complement activation in COVID-19 multiorgan impact. Kidney International, 2020, 98, 314-322.	2.6	268
721	Complement-Mediated Disorders in Pregnancy. Advances in Chronic Kidney Disease, 2020, 27, 155-164.	0.6	16
722	A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity. International Journal of Molecular Sciences, 2020, 21, 3886.	1.8	23
723	A case report of recurrent acute pancreatitis associated with life threatening atypical hemolytic uremic syndrome. Medicine (United States), 2020, 99, e19731.	0.4	5
724	Atypical Hemolytic Uremic Syndrome following Acute Type A Aortic Dissection. Case Reports in Hematology, 2020, 2020, 1-4.	0.3	4
725	â€˜Minimal symptom expressionâ€™ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. Journal of Neurology, 2020, 267, 1991-2001.	1.8	30
726	Antibodyâ€mediated complement activation in pathology and protection. Immunology and Cell Biology, 2020, 98, 305-317.	1.0	54
727	A randomized, doubleâ€blind, singleâ€dose, threeâ€arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris^{Â®}) in healthy male subjects. European Journal of Haematology, 2020, 105, 66-74.	1.1	19
728	Isolated thrombotic microangiopathy of the small intestine in a patient with atypical hemolytic uremic syndrome â€“ a case report. BMC Nephrology, 2020, 21, 104.	0.8	5
729	When to consider targeted therapies in thrombotic microangiopathies in the modern era: walking the tightrope between cost, safety, and efficacy. Journal of Thrombosis and Thrombolysis, 2020, 49, 602-605.	1.0	2
730	Sex Differences in Clinical Presentation and Outcomes among Patients with Complement-Gene-Variant-Mediated Thrombotic Microangiopathy. Journal of Clinical Medicine, 2020, 9, 964.	1.0	5
731	The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naÃ¯ve to complement inhibitor treatment. Kidney International, 2020, 97, 1287-1296.	2.6	123
732	Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties. Kidney International, 2020, 98, 1135-1148.	2.6	28
733	Tackling COVIDâ€19 infection through complementâ€targeted immunotherapy. British Journal of Pharmacology, 2021, 178, 2832-2848.	2.7	39
734	Late renal recovery after treatment over 1â€‰year post-onset in an atypical hemolytic uremic syndrome: a case report. BMC Nephrology, 2020, 21, 236.	0.8	2
735	Distinct genetic profile with recurrent population-specific missense variants in Korean adult atypical hemolytic uremic syndrome. Thrombosis Research, 2020, 194, 45-53.	0.8	4

#	Article	IF	Citations
736	Eculizumab for the treatment of myasthenia gravis. Expert Opinion on Biological Therapy, 2020, 20, 991-998.	1.4	10
737	Thrombotic microangiopathy, DIC-syndrome and COVID-19: link with pregnancy prothrombotic state. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 2536-2544.	0.7	13
738	Case Report: Carfilzomib-induced Thrombotic Microangiopathy With Complement Activation Treated Successfully With Eculizumab. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e155-e157.	0.2	16
739	European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) Complement Guideline: Deficiencies, Diagnosis, and Management. Journal of Clinical Immunology, 2020, 40, 576-591.	2.0	43
740	A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen alloâ€immunized patients. British Journal of Haematology, 2020, 189, 551-558.	1.2	17
741	Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding. Internal Medicine, 2020, 59, 93-99.	0.3	4
742	Innate immunity in diabetic kidney disease. Nature Reviews Nephrology, 2020, 16, 206-222.	4.1	273
743	Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-BarrÃ© syndrome. The Cochrane Library, 2020, 2020, CD008630.	1.5	19
744	A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease. International Journal of Molecular Sciences, 2020, 21, 525.	1.8	21
745	Clinical Characteristics and Outcome of Canadian Patients Diagnosed With Atypical Hemolytic Uremic Syndrome. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435811989722.	0.6	5
746	Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review. Toxins, 2020, 12, 67.	1.5	128
747	Typical and Atypical Hemolytic Uremic Syndrome in the Critically Ill. Critical Care Clinics, 2020, 36, 333-356.	1.0	24
748	Dengue virus and the complement alternative pathway. FEBS Letters, 2020, 594, 2543-2555.	1.3	20
749	Chronic thrombotic microangiopathy in patients with a C3 gain of function protein. Nephrology Dialysis Transplantation, 2020, 35, 1449-1451.	0.4	3
750	Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology. Frontiers in Immunology, 2020, 11, 776.	2.2	59
751	Thrombocytopenia-Associated Multiple Organ Failure. Critical Care Clinics, 2020, 36, 379-390.	1.0	15
752	Pretransplant Genetic Susceptibility: Clinical Relevance in Transplant-Associated Thrombotic Microangiopathy. Thrombosis and Haemostasis, 2020, 120, 638-646.	1.8	33
753	Treatment of thrombotic antiphospholipid syndrome in adults and children. Current Opinion in Rheumatology, 2020, 32, 215-227.	2.0	8

#	Article	IF	Citations
754	One concept does not fit all: the immune system in different forms of acute kidney injury. Nephrology Dialysis Transplantation, 2021, 36, 29-38.	0.4	11
755	Atypical hemolytic uremic syndrome in Brazil: clinical presentation, genetic findings and outcomes of a case series in adults and children treated with eculizumab. CKJ: Clinical Kidney Journal, 2021, 14, 1126-1135.	1.4	8
756	Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis. Pediatric Nephrology, 2021, 36, 463-471.	0.9	6
757	New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab. Annals of Pharmacotherapy, 2021, 55, 330-343.	0.9	5
758	Early initiation of eculizumab therapy for Streptococcus pneumoniaeâ€“associated hemolytic uremic syndrome. Pediatric Blood and Cancer, 2021, 68, e28589.	0.8	3
759	The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatric Nephrology, 2021, 36, 889-898.	0.9	35
760	Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood, 2021, 137, 2438-2449.	0.6	87
761	Transplantation in pediatric aHUS within the era of eculizumab therapy. Pediatric Transplantation, 2021, 25, e13914.	0.5	2
762	Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension. Neurology, 2021, 96, e610-e618.	1.5	46
763	Severely ill pediatric patients with Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) who suffered from multiple organ involvement in the early stage. Pediatric Nephrology, 2021, 36, 1499-1509.	0.9	11
764	Monitoring Ravulizumab effect on complement assays. Journal of Immunological Methods, 2021, 490, 112944.	0.6	9
765	Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity. Blood, 2021, 137, 443-455.	0.6	55
766	Efficacy of Eculizumab in Coexisting Complement C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome. Kidney International Reports, 2021, 6, 534-537.	0.4	8
768	Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: Lessons from a prospective multicentric study. British Journal of Clinical Pharmacology, 2021, 87, 2236-2246.	1.1	10
769	Early detection of atypical hemolytic uremic syndrome through home urine test: a sibling case report. Japanese Journal of Pediatric Nephrology, 2021, 34, .	0.0	0
770	Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis. BMC Nephrology, 2021, 22, 5.	0.8	14
771	Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient. Frontiers in Immunology, 2020, 11, 612706.	2.2	9
772	Complement, a Therapeutic Target in Diabetic Kidney Disease. Frontiers in Medicine, 2020, 7, 599236.	1.2	17

#	Article	IF	Citations
773	Thrombotic microangiopathy secondary to recurrent prostate cancer. Clinical Nephrology Case Studies, 2021, 9, 105-109.	0.3	0
774	The Benefits of Complement Measurements for the Clinical Practice. Methods in Molecular Biology, 2021, 2227, 1-20.	0.4	2
775	Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes. CKJ: Clinical Kidney Journal, 2021, 14, 2075-2084.	1.4	9
776	Uncommon presentation of atypical hemolytic uremic syndrome: A Case Report. Indian Journal of Nephrology, 2021, 31, 478.	0.2	0
777	Complement as a Therapeutic Target in Systemic Autoimmune Diseases. Cells, 2021, 10, 148.	1.8	18
778	Changing Definition of Immunosuppression: Targeted Therapies and Resulting Emerging Infections and Their Prevention. , 2021, , 25-41.		0
779	Kidney and urinary tract disorders. , 2021, , 167-228.		2
780	Activated Prothrombin Complex Concentrate-Induced Atypical Hemolytic Uremic Syndrome Treated with Eculizumab. American Journal of Case Reports, 2021, 22, e929616.	0.3	2
781	Overcoming innate immune barriers that impede AAV gene therapy vectors. Journal of Clinical Investigation, 2021, 131, .	3.9	72
782	Management and treatment of glomerular diseases (part 2): Conclusions From A Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Nephrology (Saint-Petersburg), 2021, 25, 96-119.	0.1	3
783	Advances in treating myasthenia gravis. , 2021, , 243-264.		0
784	Complement-5 Inhibition Deters Progression of Fulminant Hepatitis to Acute Liver Failure in Murine Models. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1351-1367.	2.3	6
785	A rare cause of recurrent acute kidney injury in a 3-year-old girl: Answers. Pediatric Nephrology, 2021, 36, 2033-2037.	0.9	1
786	Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan. Amino Acids, 2021, 53, 143-147.	1.2	12
788	Carfilzomib-induced atypical haemolytic uraemic syndrome: a diagnostic challenge and therapeutic success. BMJ Case Reports, 2021, 14, e239091.	0.2	8
789	Benefit and danger from immunotherapy in myasthenia gravis. Neurological Sciences, 2021, 42, 1367-1375.	0.9	7
790	Retrospective and Systematic Analysis of Causes and Outcomes of Thrombotic Microangiopathies in Routine Clinical Practice: An 11-Year Study. Frontiers in Medicine, 2021, 8, 566678.	1.2	9
791	The interplay between neutrophils, complement, and microthrombi in COVID-19. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101661.	1.4	35

#	Article	IF	Citations
792	Eculizumab exposure in children and young adults: indications, practice patterns, and outcomesâ€"a Pediatric Nephrology Research Consortium study. Pediatric Nephrology, 2021, 36, 2349-2360.	0.9	6
794	Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome. Blood Advances, 2021, 5, 1504-1512.	2.5	13
795	Eculizumab therapy on a patient with coâ€existent lupus nephritis and C3 mutationâ€related atypical haemolytic uremic syndrome: a case report. BMC Nephrology, 2021, 22, 86.	0.8	3
796	Post-traumatic thrombotic microangiopathy: What trauma surgeons need to know?. Chinese Journal of Traumatology - English Edition, 2021, 24, 69-74.	0.7	4
797	Interventions for atypical haemolytic uraemic syndrome. The Cochrane Library, 2021, 2021, CD012862.	1.5	8
798	Complement in Sickle Cell Disease: Are We Ready for Prime Time?. Journal of Blood Medicine, 2021, Volume 12, 177-187.	0.7	8
799	Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacological Reviews, 2021, 73, 792-827.	7.1	97
800	Complement-Mediated Thrombotic Microangiopathy Associated with Lupus Nephritis Treated with Eculizumab: A Case Report. Case Reports in Nephrology and Dialysis, 2021, 11, 95-102.	0.3	6
801	Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults. Kidney International Reports, 2021, 6, 1603-1613.	0.4	29
802	Acute ST-Segment Elevation Myocardial Infarction as Initial Presentation of Atypical Hemolytic-Uremic Syndrome. JACC: Case Reports, 2021, 3, 561-565.	0.3	0
803	Functional and Genetic Landscape of Complement Dysregulation Along the Spectrum of Thrombotic Microangiopathy and its Potential Implications on Clinical Outcomes. Kidney International Reports, 2021, 6, 1099-1109.	0.4	13
804	Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis. Journal of Nephrology, 2021, 34, 1581-1590.	0.9	23
805	Thrombotic Microangiopathy After Kidney Transplantation: An Underdiagnosed and Potentially Reversible Entity. Frontiers in Medicine, 2021, 8, 642864.	1.2	15
806	An update: the emerging evidence of complement involvement in COVID-19. Medical Microbiology and Immunology, 2021, 210, 101-109.	2.6	15
807	Kidney transplant in patients with atypical hemolytic uremic syndrome in the anti-C5 era: single-center experience with tailored Eculizumab. Journal of Nephrology, 2021, 34, 2027-2036.	0.9	5
808	Eculizumab and aHUS: to stop or not. Blood, 2021, 137, 2419-2420.	0.6	14
809	COVID-19 in a kidney transplant recipient treated with eculizumab for atypical hemolytic uremic syndrome: a case report. Journal of Nephrology, 2021, 34, 1045-1048.	0.9	4
810	Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nature Reviews Nephrology, 2021, 17, 543-553.	4.1	64

#	Article	IF	Citations
811	IgA vasculitis complicated by acute kidney failure with thrombotic microangiopathy: successful use of eculizumab. Journal of Nephrology, 2021, 34, 2141-2145.	0.9	2
812	Ravulizumab for the Treatment of aHUS in Adults: Improving Quality of Life. Kidney International Reports, 2021, 6, 1489-1491.	0.4	5
813	Treatment of Gemcitabine-Induced Thrombotic Microangiopathy Followed by Gemcitabine Rechallenge With Eculizumab. Kidney International Reports, 2021, 6, 1464-1468.	0.4	9
814	Complement Components in the Diagnosis and Treatment after Kidney Transplantationâ€"Is There a Missing Link?. Biomolecules, 2021, 11, 773.	1.8	3
815	Complement, inflammation and thrombosis. British Journal of Pharmacology, 2021, 178, 2892-2904.	2.7	39
816	Strategies to Uplift Novel Mendelian Gene Discovery for Improved Clinical Outcomes. Frontiers in Genetics, 2021, 12, 674295.	1.1	23
817	Nanobodies: new avenue to treat kidney disease. Cell and Tissue Research, 2021, 385, 445-456.	1.5	6
818	The standard of care for immune thrombotic thrombocytopenic purpura today. Journal of Thrombosis and Haemostasis, 2021, 19, 1864-1871.	1.9	12
819	Successful treatment with eculizumab in a patient with pregnancy-associated atypical hemolytic uremic syndrome. Obstetric Medicine, 0, , 1753495X2110199.	0.5	0
820	Systemic autoimmune disorders associated with thrombotic microangiopathy: A cross-sectional analysis from the French National TMA registry: Systemic autoimmune disease-associated TMA. European Journal of Internal Medicine, 2021, 93, 78-86.	1.0	9
821	Indicators Differentiating Thrombotic Thrombocytopenic Purpura From Other Thrombotic Microangiopathies in a Canadian Apheresis Referral Center. American Journal of Clinical Pathology, 2021, 156, 1103-1112.	0.4	2
822	Lessons for the clinical nephrologist: recurrent pregnancy-associated thrombotic microangiopathy (TMA) with a known complement mutation and features of preeclampsia; a diagnostic and therapeutic dilemma. Journal of Nephrology, 2021, 34, 1673-1676.	0.9	2
823	Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy. Frontiers in Immunology, 2021, 12, 680567.	2.2	24
824	Current and Evolving Indications for Simultaneous Liver Kidney Transplantation. Seminars in Liver Disease, 2021, 41, 308-320.	1.8	0
825	Canonical and nonâ€canonical functions of the complement system in health and disease. British Journal of Pharmacology, 2021, 178, 2751-2753.	2.7	4
826	COVID-19 and thrombotic microangiopathies. Thrombosis Research, 2021, 202, 191-198.	0.8	57
827	Familial atypical hemolytic uremic syndrome with positive p.S1191L (c.3572C>T) mutation on the CFH gene: A single-center experience. Balkan Journal of Medical Genetics, 2021, 24, 81-88.	0.5	0
828	Clostridioides difficile-Associated Atypical Hemolytic-Uremic Syndrome Successfully Treated With Eculizumab: A Case Report and Literature Review. , 2021, 3, e0475.		0

#	Article	IF	Citations
829	Presumed complement-mediated, checkpoint inhibitor-induced, thrombotic microangiopathy in a patient with metastatic melanoma. BMJ Case Reports, 2021, 14, e242075.	0.2	6
830	The Syndromes of Thrombotic Microangiopathy: A Critical Appraisal on Complement Dysregulation. Journal of Clinical Medicine, 2021, 10, 3034.	1.0	12
831	Utility Values Associated with Atypical Hemolytic Uremic Syndrome-Related Attributes: A Discrete Choice Experiment in Five Countries. Pharmacoeconomics, 2021, 39, 901-912.	1.7	6
832	Early relapse of atypical hemolytic uremic syndrome following ABO-incompatible livingâ€“related pediatric kidney re-transplant successfully treated with eculizumab. Pediatric Nephrology, 2021, 36, 3271-3275.	0.9	3
833	Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice. Nephrology Dialysis Transplantation, 2022, 37, 239-254.	0.4	63
834	Complement in sickle cell disease and targeted therapy: I know one thing, that I know nothing. Blood Reviews, 2021, 48, 100805.	2.8	12
835	Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre. BMC Nephrology, 2021, 22, 267.	0.8	24
836	Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With Eculizumab. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e845-e849.	0.2	5
837	Complement and the prothrombotic state. Blood, 2022, 139, 1954-1972.	0.6	15
838	Microangiopathic Haemolytic Anaemia in a Young Male Patient With Oesophageal Carcinoma. Cureus, 2021, 13, e17479.	0.2	0
839	Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne, 2021, .	0.3	1
840	Thrombotic microangiopathy following aortic surgery with hypothermic circulatory arrest: a single-centre experience of an underestimated cause of acute renal failure. Interactive Cardiovascular and Thoracic Surgery, 2022, 34, 258-266.	0.5	3
841	Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist. American Journal of Hematology, 2021, 96, 1655-1665.	2.0	16
842	Differentiating Hemolysis, Elevated Liver Enzymes, and Low Platelet Count Syndrome and Atypical Hemolytic Uremic Syndrome in the Postpartum Period. Hypertension, 2021, 78, 760-768.	1.3	11
843	Case Report: Eculizumab and ECMO Rescue Therapy of Severe ARDS in Goodpasture Syndrome. Frontiers in Medicine, 2021, 8, 720949.	1.2	5
844	Upregulation of Nrf2 Attenuates Oxidative Stressâ€“Induced, Complement Activationâ€“Associated Endothelial Injury and Apoptosis in Transplant-Associated Thrombotic Microangiopathy. Transplantation and Cellular Therapy, 2021, 27, 758.e1-758.e8.	0.6	5
845	De Novo and Recurrent Thrombotic Microangiopathy After Renal Transplantation: Current Concepts in Management. Experimental and Clinical Transplantation, 2022, 20, 549-557.	0.2	2
846	Rare Presentation of Atypical Hemolytic Uremic Syndrome in an Adult. Cureus, 2021, 13, e18184.	0.2	0

#	Article	IF	Citations
847	Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of <scp>REGAIN</scp> and its extension study. Muscle and Nerve, 2021, 64, 662-669.	1.0	11
848	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, S1-S276.	2.6	782
849	Thrombotic microangiopathy during pregnancy. Microvascular Research, 2021, 138, 104226.	1.1	10
850	Purtscher-like Retinopathy Associated with Atypical Hemolytic Uremic Syndrome. Retinal Cases and Brief Reports, 2021, Publish Ahead of Print, .	0.3	2
851	Pregnancy-Associated Thrombotic Thrombocytopenic Purpura and Hemolytic-Uremic Syndrome. , 2021, , 91-108.		0
852	A Case of Gemcitabine-Induced Thrombotic Microangiopathy Treated With Ravulizumab in a Patient With Stage IV Pancreatic Cancer. Cureus, 2021, 13, e13031.	0.2	1
853	Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2020, 11, 564647.	2.2	25
854	Eculizumab interruption in atypical hemolytic uremic syndrome due to shortage: analysis of a Brazilian cohort. Journal of Nephrology, 2021, 34, 1373-1380.	0.9	8
855	Integration with Kidney Disease Improving Global Outcomes (KDIGO). , 2018, , 1-9.		5
856	GlomerulÃre Erkrankungen. , 2017, , 69-123.		1
857	Complement catalyzing glomerular diseases. Cell and Tissue Research, 2021, 385, 355-370.	1.5	15
858	Hemolytic Anemia. Physician Assistant Clinics, 2019, 4, 649-662.	0.1	2
859	Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective. Saudi Pharmaceutical Journal, 2020, 28, 1333-1352.	1.2	21
861	Thrombotic microangiopathies assessment: mind the complement. CKJ: Clinical Kidney Journal, 2021, 14, 1055-1066.	1.4	14
862	Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal. CKJ: Clinical Kidney Journal, 2021, 14, 1939-1945.	1.4	5
863	Sepsis-induced Coagulopathy and Disseminated Intravascular Coagulation. Anesthesiology, 2020, 132, 1238-1245.	1.3	99
864	The importance of genetic mutation screening to determine retransplantation following failed kidney allograft from recurrent atypical haemolytic ureamic syndrome. BMJ Case Reports, 2014, 2014, bcr2013202875-bcr2013202875.	0.2	4
865	Thrombotic microangiopathy associated with intravenous injection of extended-release oxycodone. BMJ Case Reports, 2017, 2017, bcr-2017-220977.	0.2	4

#	Article	IF	Citations
866	Complementopathies and precision medicine. Journal of Clinical Investigation, 2020, 130, 2152-2163.	3.9	70
867	Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice. Journal of Clinical Investigation, 2019, 129, 1061-1075.	3.9	23
868	Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndromeâ€“ a single center experience. BMC Nephrology, 2020, 21, 189.	0.8	11
869	A Case Report and Literature Review of Eculizumab Withdrawal in Atypical Hemolytic-Uremic Syndrome. American Journal of Case Reports, 2016, 17, 950-956.	0.3	5
870	Relapse of Atypical Hemolytic Uremic Syndrome During Pregnancy in a Patient on Eculizumab Maintenance Treatment: A Case Report. American Journal of Case Reports, 2019, 20, 1460-1465.	0.3	5
871	Recent advances in understanding and management of acquired thrombocytopenia. F1000Research, 2018, 7, 68.	0.8	5
872	Haemolytic uremic syndrome: diagnosis and management. F1000Research, 2019, 8, 1690.	0.8	23
873	Late Presentation of Carfilzomib Associated Thrombotic Microangiopathy. American Journal of Medical Case Reports, 2019, 7, 240-243.	0.1	10
874	Management of hemolytic uremic syndrome. F1000prime Reports, 2014, 6, 119.	5.9	19
875	Severe Case of Thrombotic Microangiopathy with a Delayed Diagnosis of Atypical Haemolytic Uraemic Syndrome Successfully Managed with Eculizumab. European Journal of Case Reports in Internal Medicine, 2015, 2, .	0.2	1
876	Netrin-1 Reduces Monocyte and Macrophage Chemotaxis towards the Complement Component C5a. PLoS ONE, 2016, 11, e0160685.	1.1	13
877	Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome. PLoS ONE, 2017, 12, e0177894.	1.1	16
879	Complement Inhibition for the Treatment of Myasthenia Gravis . ImmunoTargets and Therapy, 2020, Volume 9, 317-331.	2.7	27
880	A Simplified Approach to the Diagnosis of Atypical HUS: Clinical Considerations and Practical Implications. The Open Urology & Nephrology Journal, 2014, 7, 91-94.	0.2	5
881	A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-BarrÃ© Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS). JMIR Research Protocols, 2016, 5, e210.	0.5	18
882	Atypical hemolytic uremic syndrome and eculizumab therapy in children. Korean Journal of Pediatrics, 2018, 61, 37.	1.9	3
883	Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean Journal of Internal Medicine, 2020, 35, 25-40.	0.7	22
884	Thrombotic microangiopathies: Similar presentations, different therapies. Cleveland Clinic Journal of Medicine, 2017, 84, 114-130.	0.6	12

#	Article	IF	Citations
885	Eculizumab for atypical hemolytic-uremic syndrome in India: First report from India and the challenges faced. Indian Journal of Nephrology, 2017, 27, 58.	0.2	8
886	Eculizumab dosing in infants. Indian Journal of Nephrology, 2018, 28, 73.	0.2	2
887	Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Consensus Based Diagnostic and Therapeutic Recommendations: Which TA-TMA Patients to Treat and When?. Journal of Bone Marrow Research, 2014, 02, .	0.2	9
888	Cancer-related microangiopathic hemolytic anemia in patients with advanced gastric cancer: A retrospective single-center analysis. World Journal of Gastrointestinal Oncology, 2020, 12, 1288-1295.	0.8	1
889	The Role of Complement Inhibition in Thrombotic Angiopathies and Antiphospholipid Syndrome. Turkish Journal of Haematology, 2016, 33, 1-7.	0.2	38
890	Thrombotic Microangiopathy with Renal Injury: An Approach for the General Physician. Journal of the Royal College of Physicians of Edinburgh, The, 2020, 50, 25-31.	0.2	3
891	Successful eculizumab treatment of recurrent postpartum atypical hemolytic uremic syndrome after kidney transplantation. Clinical Nephrology Case Studies, 2015, 3, 8-13.	0.3	3
892	Eculizumab in chemotherapy-induced thrombotic microangiopathy. Clinical Nephrology Case Studies, 2020, 8, 25-32.	0.3	9
893	Eculizumab for pediatric dense deposit disease: A case report and literature review. Clinical Nephrology Case Studies, 2020, 8, 96-102.	0.3	3
894	Complement cascade and kidney transplantation: The rediscovery of an ancient enemy. World Journal of Transplantation, 2014, 4, 168.	0.6	8
895	Thrombotic microangiopathy after renal transplantation: Current insights inde novoand recurrent disease. World Journal of Transplantation, 2018, 8, 122-141.	0.6	35
896	Complement involvement in kidney diseases: From physiopathology to therapeutical targeting. World Journal of Nephrology, 2015, 4, 169.	0.8	16
897	Hemolytic-Uremic Syndrome in childhood. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2014, 36, 208-220.	0.4	5
898	The role of complement in kidney disease. Clinical Medicine, 2020, 20, 156-160.	0.8	26
899	Atypical Hemolytic Uremic Syndrome and Chronic Ulcerative Colitis Treated with Eculizumab. International Journal of Medical and Pharmaceutical Case Reports, 2015, 4, 105-112.	0.0	13
900	Novel Selection Approaches to Identify Antibodies Targeting Neoepitopes on the C5b6 Intermediate Complex to Inhibit Membrane Attack Complex Formation. Antibodies, 2021, 10, 39.	1.2	0
901	Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series. Brain Sciences, 2021, 11, 1341.	1.1	7
902	Complement Factor H Gene Variant in a Patient with Thrombotic Microangiopathy on a Mixed Clinical Background. Case Reports in Nephrology, 2021, 2021, 1-6.	0.2	0

#	Article	IF	Citations
903	Utilization Pattern for Eculizumab Among Children With Hemolytic Uremic Syndrome. Frontiers in Pediatrics, 2021, 9, 733042.	0.9	0
904	Questions and guide to answers. The Egyptian Journal of Internal Medicine, 2013, 25, 232.	0.3	0
905	Diagnosing Thrombocytopenia in the Clinic. , 2014, , 99-113.		0
906	Thrombotic Microangiopathies. , 2014, , 323-330.		0
907	Current review of aHUS. Japanese Journal of Thrombosis and Hemostasis, 2014, 25, 697-705.	0.1	0
908	Thrombocytopenia-Associated Multiple Organ Failure Syndrome. , 2014, , 481-492.		2
909	Chronic Kidney Disease (CKD). , 2014, , 145-150.		2
910	Questions and guide to answers. The Egyptian Journal of Internal Medicine, 2014, 26, 93-96.	0.3	0
911	Thrombotic Microangiopathy (TTP/HUS). , 2015, , 57-62.		1
912	HÃmolytisch-urÃmisches Syndrom. , 2015, , P17.1-P17.5.		0
913	Hemolytic-uremic syndrome: Etiopathogenesis, diagnostics and basic principles of treatment. Medicinski Casopis, 2015, 49, 59-65.	0.1	2
914	Complement and Complement Regulatory Proteins in Diabetes. , 2015, , 29-57.		1
915	Expansions to New Campuses and Integrated Research. , 2015, , 61-89.		0
916	Renal Involvement in Children with HUS. , 2015, , 1-37.		0
917	Eculizumab for Gemcitabine-Induced Hemolytic Uremic Syndrome: A Novel Therapy for an Emerging Condition. The Medicine Forum, 2015, 16, .	0.0	1
918	RÃ©animation des patients dâ€™onco-hÃ©matologie : nouvelles thÃ©rapeutiques, nouvelles complications, nouveaux contrats dâ€™admission. Bulletin De L'Academie Nationale De Medecine, 2015, 199, 293-312.	0.0	0
919	SÃndrome hemolÃtico urÃ©mico atÃpico, revisiÃ³n de la literatura y documento de consenso. Enfoque diagnÃ³stico y tratamiento. Revista Colombiana De NefrologÃa, 2015, 2, 19-40.	0.1	4
921	Complement-Mediated Glomerular Injury in Children. , 2016, , 927-958.		0

#	Article	IF	Citations
922	TROMBINIÅ² MIKROANGIOPATIJÅ² SINDROMÅ² PATOGENETINIAI MECHANIZMAI, DIFERENCINÄ– DIAGNOSTIKA IR GYDYMAS. Medicinos Teorija Ir Praktika, 2015, 21, 675-682.	0.0	0
923	Complement in hemolytic anemia. Hematology American Society of Hematology Education Program, 2015, 2015, 385-391.	0.9	0
924	Introduction to Thrombotic Microangiopathies. , 2016, , 518-523.		0
926	Acute Renal Failure (Acute Kidney Injury) in Pregnancy. , 2016, , 45-56.		0
927	Rituximab-related posterior reversible encephalopathy syndrome in HUS patient post kidney transplant. International Journal of Case Reports and Images, 2016, 7, 135.	0.0	2
928	The Nature of the Diseases That Arise from Improper Regulation of the Alternative Pathway of Complement. , 0, , 138-144.		0
929	A case of atypical hemolytic uremic syndrome triggered by a surgery, and treated with eculizumab. Journal of the Japanese Society of Intensive Care Medicine, 2016, 23, 673-674.	0.0	0
930	The Role of Complement in Disease. , 2016, , 583-596.		1
931	Atypical Hemolytic-Uremic Syndrome: From Pathogenesis to Therapy. Giornale De Techniche Nefrologiche & Dialitiche, 2016, 28, 216-218.	0.1	0
932	An Atypical Cause Of Atypical Hemolytic Uremic Syndrome. Marshall Journal of Medicine, 2016, 2, .	0.1	1
933	Infection Prevention in Chronic Kidney Disease/Dialysis/Transplant. Journal of Pediatric Infectious Diseases, 2016, 11, 79-85.	0.1	0
934	Complement and PNH. , 2017, , 67-95.		0
936	POSTPARTUM ATYPICAL HEMOLYTIC UREMIC SYNDROME. CLINICAL OBSERVATIONS AND HISTOLOGICAL FEATURES. Nephrology (Saint-Petersburg), 2017, 21, 98-106.	0.1	0
937	Atypical hemolytic uremic syndrome and current view on the treatment. Interni Medicina Pro Praxi, 2017, 19, 116-124.	0.0	1
938	Atypical haemolytic uremic syndrome (aHUS) and membranoproliferative glomerulonephritis (MPGN), different diseases or a spectrum of complement-mediated glomerular diseases?. BMJ Case Reports, 2017, 2017, bcr-2017-220974.	0.2	6
939	Hematologic Complications Associated with HSCT. , 2018, , 283-299.		0
940	Atypical hemolytic-uremic syndrome due to complement factor I mutation. World Journal of Nephrology, 2017, 6, 243-250.	0.8	3
942	Background and Presentation of Thrombotic Thrombocytopenic Purpura. , 2018, , 153-169.		0

#	Article	IF	Citations
943	Time to Change the Plasma. , 2018, , 281-284.		0
944	Hemolytic Uremic Syndrome, Genetic. , 2018, , 1-13.		0
945	ATYPICAL HEMOLYTIC UREMIC SYNDROME AND C3 GLOMERULOPATHY: CONCLUSIONS FROM A Â«KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMESÂ» (KDIGO) CONTROVERSIES CONFERENCE. Nephrology (Saint-Petersburg), 2018, 22, 18-39.	0.1	0
946	Therapeutic Apheresis in Critically Ill Patients. , 2019, , 1154-1160.e2.		0
947	ã,¨ãƒ©ãƒ¼ã,¿ï¼šé¾å…¸åž‹æº¶è¡€æ€§å°¿æ¯’ç´ç—‡å€™ç¾¤ï¼ˆaHUSï¼‰. Japanese Journal of Thrombosis and Hemostasis, 2019, 30, 16	0.1	0
948	Differential Diagnosis and Treatment of Thrombotic Microangiopathy Syndrome. Korean Journal of Medicine, 2019, 94, 83-88.	0.1	0
949	Complement-Inhibiting Therapy of Atypical Haemolytic Uremic Syndrome in a Patient With Factor H Mutation. PediatriÄeskaÃ¢ FarmakologiÃ¢, 2019, 15, 470-478.	0.1	0
950	Atypical Hemolytic Uremic Syndrome With the p.Ile1157Thr C3 Mutation Successfully Treated With Plasma Exchange and Eculizumab: A Case Report. , 2019, 1, e0008.		2
951	Articular and skeletal affection in regularly dialyzed patients with end-stage renal disease. Egyptian Rheumatology and Rehabilitation, 2019, 46, 162-169.	0.2	0
952	Therapeutic Plasma Exchange and Immunoadsorption: Indications and Implementation. Advances and Controversies in Hematopoietic Transplantation and Cell Therapy, 2020, , 135-150.	0.0	0
953	Treatment Options in Patients Suffering from Hemolytic-Uremic Syndrome: The Serbian Military Medical Academy Experience. Serbian Journal of Experimental and Clinical Research, 2022, 23, 237-242.	0.2	0
954	Changing Definition of Immunosuppression: Targeted Therapies and Resulting Emerging Infections and Their Prevention. , 2020, , 1-17.		0
955	Case report and case series. Kerala Journal of Psychiatry, 2020, 33, .	0.1	0
957	Case Report of Rare Entity for Atypical Hemolytic Uremic Syndrome. MVP Journal of Medical Sciences, 2020, 7, 129-134.	0.1	0
959	The emerging role of complement in neuromuscular disorders. Seminars in Immunopathology, 2021, 43, 817-828.	2.8	9
960	Haemolytic uraemic syndrome. , 2020, , 5027-5032.		0
961	Developments in immunosuppression. Current Opinion in Organ Transplantation, 2021, 26, 91-96.	0.8	9
963	Exploring the role of the complement system, endothelial injury, and microRNAs in thrombotic microangiopathy after kidney transplantation. Journal of International Medical Research, 2020, 48, 030006052098053.	0.4	1

#	Article	IF	Citations
964	Renal Manifestations in Lupus Pregnancy. , 2020, , 61-76.		0
965	Urgent plasma exchange in the treatment of thrombotic microangiopathy in postpartum period in women. Russian Journal of Anesthesiology and Reanimatology /Anesteziologiya I Reanimatologiya, 2020, , 85.	0.2	0
966	Thrombotic Microangiopathy in the Adolescent Female. , 2020, , 279-288.		0
967	A case of hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli after pericardiectomy. Clinical Journal of Gastroenterology, 2021, , 1.	0.4	2
968	Atypical Hemolytic Uremic Syndrome in a Patient With Bothrops asper Envenomation. Wilderness and Environmental Medicine, 2022, 33, 109-115.	0.4	4
969	Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort. PLoS ONE, 2021, 16, e0258319.	1.1	5
970	Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis. Frontiers in Neurology, 2021, 12, 696385.	1.1	8
972	Atypical Hemolytic Uremic Syndrome After Liver Transplant Treated With Eculizumab. Cureus, 2020, 12, e9230.	0.2	2
973	IV. Diagnosis and Treatment of Atypical Hemolytic Uremic Syndrome. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 1363-1369.	0.0	0
974	Vasculopathy in patients with severe COVID-19 infection. Klinicheskaia Meditsina, 2020, 98, 325-333.	0.2	3
975	Combined liver-kidney transplantation for rare diseases. World Journal of Hepatology, 2020, 12, 722-737.	0.8	1
976	Primary Nephritic Syndromes. Nephrology Self-assessment Program: NephSAP, 2020, 19, 77-87.	3.0	0
977	Diagnosis of atypical hemolytic uremic syndrome and response to eculizumab therapy. Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health, 2014, 73, 22-4.	0.4	4
978	Hypertensive Crisis and Refractory Hypertension Caused by Atypical Hemolytic Uremic Syndrome and Effect of Eculizumab. Acta Cardiologica Sinica, 2018, 34, 446-449.	0.1	2
979	The Most Expensive Drug in the World: To Continue or Discontinue, That Is the Question. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2016, 33, 22-28.	0.6	3
980	Atypical Hemolytic Uremic Syndrome: Genetic Landscape Challenge. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2019, 30, 340-345.	0.7	1
981	Acute kidney injuries induced by thrombotic microangiopathy following severe hemorrhage in puerperants: a case series and literature review. American Journal of Translational Research (discontinued), 2021, 13, 6182-6190.	0.0	1
982	Hematologic manifestations of systemic illness. , 2022, , 7-35.		0

#	Article	IF	Citations
983	Treatment of Shiga-Toxin Hus with Severe Neurologic Features with Eculizumab. Case Reports in Pediatrics, 2021, 2021, 1-6.	0.2	1
984	Thrombotic Microangiopathy, an Unusual Form of Monoclonal Gammopathy of Renal Significance: Report of 3 Cases and Literature Review. Frontiers in Immunology, 2021, 12, 780107.	2.2	9
985	C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. Blood Advances, 2022, 6, 866-881.	2.5	31
986	Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics. Advances in Immunology, 2021, 152, 1-81.	1.1	7
987	Gemcitabine-Induced Hemolytic Uremic Syndrome in Lung Cancer: A Case Report. Cureus, 2022, 14, e20926.	0.2	0
988	Eculizumab treatment in atypical hemolytic uremic syndrome: correlation between functional complement tests and drug levels. Journal of Nephrology, 2022, 35, 1205-1211.	0.9	2
989	Hematology Emergencies in Critically Ill Adults. Chest, 2022, 161, 1285-1296.	0.4	3
990	Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT. Blood Advances, 2022, 6, 1454-1463.	2.5	10
991	Assessing and counteracting fibrosis is a cornerstone of the treatment of CKD secondary to systemic and renal limited autoimmune disorders. Autoimmunity Reviews, 2022, 21, 103014.	2.5	11
992	Eculizumab treatment and discontinuation in pediatric patients with atypical hemolytic uremic syndrome: a multicentric retrospective study. Journal of Nephrology, 2022, , 1.	0.9	3
993	Thrombotic microangiopathy in children. Pediatric Nephrology, 2022, 37, 1967-1980.	0.9	14
994	Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome. Journal of Medical Economics, 2022, 25, 249-259.	1.0	6
995	Complement ratios C3bc/C3 and sC5b-9/C5 do not increase the sensitivity of detecting acute complement activation systemically. Molecular Immunology, 2022, 141, 273-279.	1.0	2
996	The Glomerulus According to the Mesangium. Frontiers in Medicine, 2021, 8, 740527.	1.2	12
997	Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome. Transplantation Direct, 2022, 8, e1289.	0.8	3
998	Vaccinations in Children and Adolescents Treated with Immune-Modifying Biologics: Update and Current Developments. Journal of Allergy and Clinical Immunology: in Practice, 2022, , .	2.0	0
999	Complement Blockade Is a Promising Therapeutic Approach in a Subset of Critically Ill Adult Patients with Complement-Mediated Hemolytic Uremic Syndromes. Journal of Clinical Medicine, 2022, 11, 790.	1.0	1
1000	Systematic review of atypical hemolytic uremic syndrome biomarkers. Pediatric Nephrology, 2022, 37, 1479-1493.	0.9	8

#	Article	IF	Citations
1001	Emerging Role of Clinical Genetics in CKD. Kidney Medicine, 2022, 4, 100435.	1.0	12
1002	Paroxysmal nocturnal haemoglobinuria (PNH): novel therapies for an ancient disease. British Journal of Haematology, 2020, 191, 579-586.	1.2	6
1003	Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data. Clinical Nephrology, 2022, 97, 261-272.	0.4	12
1004	Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management. Neurotherapeutics, 2022, 19, 897-910.	2.1	15
1005	Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19. Frontiers in Pharmacology, 2022, 13, 842473.	1.6	6
1006	Complement Activation and Thrombotic Microangiopathy Associated With Monoclonal Gammopathy: A National French Case Series. American Journal of Kidney Diseases, 2022, 80, 341-352.	2.1	7
1007	Child Neurology: Pathologically Confirmed Thrombotic Microangiopathy Caused by Onasemnogene Abeparvovec Treatment for SMA. Neurology, 2022, 98, 808-813.	1.5	12
1008	Complement inhibitor eculizumab in thrombotic microangiopathy: Singleâ€center case series. Clinical Case Reports (discontinued), 2022, 10, e05573.	0.2	0
1009	Application of C5 inhibitors in glomerular diseases in 2021. Kidney Research and Clinical Practice, 2022, 41, 412-421.	0.9	12
1010	Acute thrombocytopenia suggesting thrombotic microangiopathy. American Journal of Hematology, 2022, 97, 659-665.	2.0	1
1011	The Rational Use of Complement Inhibitors in Kidney Diseases. Kidney International Reports, 2022, 7, 1165-1178.	0.4	16
1012	Incidence and cost of haemolytic uraemic syndrome in urban China: a national population-based analysis. BMC Nephrology, 2022, 23, 122.	0.8	5
1013	Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective. Nephrology Dialysis Transplantation, 2023, 38, 362-371.	0.4	3
1014	Microangiopathic hemolytic anemia in a female patient with systemic lupus erythematosus. Cleveland Clinic Journal of Medicine, 2022, 89, 130-138.	0.6	0
1015	Maternal morbidity and mortality in pregnant/postpartum women with suspected <scp>HELLP</scp> syndrome identifiable as probable thrombotic thrombocytopenic purpura or atypical hemolytic uremic syndrome by high <scp>LDH</scp> to <scp>AST</scp> ratio. International Journal of Gynecology and Obstetrics, 2022, 159, 870-874.	1.0	2
1016	Can Urinary Complement Proteins Stratify Patients to Therapeutic Complement Inhibitors?. Kidney International Reports, 2022, 7, 939-941.	0.4	1
1018	A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics, 2022, 60, 269-279.	0.3	5
1019	Ravulizumab 100 mg/mL formulation reduces infusion time and frequency, improving the patient and caregiver experience in the treatment of atypical haemolytic uraemic syndrome. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 1081-1087.	0.7	4

#	Article	IF	Citations
1021	Uncommon Causes of Acute Kidney Injury. Critical Care Clinics, 2022, 38, 317-347.	1.0	1
1022	Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review. Leukemia and Lymphoma, 2022, 63, 1102-1110.	0.6	5
1023	Eculizumab in low-middle income countries: how much does a life cost?. Journal of Nephrology, 2022, 35, 1255-1257.	0.9	4
1024	Platelet-leukocyte crosstalk in COVID-19: How might the reciprocal links between thrombotic events and inflammatory state affect treatment strategies and disease prognosis?. Thrombosis Research, 2022, 213, 179-194.	0.8	17
1025	COVID-19 and thrombotic microangiopathy. Obstetrics, Gynecology and Reproduction, 2022, 15, 639-657.	0.2	5
1026	Is It Time to Utilize Genetic Testing for Living Kidney Donor Evaluation?. Nephron, 2022, 146, 220-226.	0.9	3
1027	Pediatric Atypical Hemolytic Uremic Syndrome Advances. Cells, 2021, 10, 3580.	1.8	18
1028	A Mortality Case Caused by Thrombotic Microangiopathy after Successful Bloodless Living Donor Liver Transplantation. Soonchunhyang Medical Science, 2021, 27, 85-87.	0.0	0
1029	Soliris to Stop Immune-Mediated Death in COVID-19 (SOLID-C19)â€"A Compassionate-Use Study of Terminal Complement Blockade in Critically Ill Patients with COVID-19-Related Adult Respiratory Distress Syndrome. Viruses, 2021, 13, 2429.	1.5	11
1030	Eculizumab Use in a Temporarily Dialysis-Dependent Patient With Shiga Toxinâ€"Producing Escherichia Coli Hemolytic Uremic Syndrome With Neurological Complications. Journal of Pediatric Pharmacology and Therapeutics, 2022, 27, 90-95.	0.3	1
1031	Clinical features and outcomes of four atypical hemolytic uremic syndrome cases at a single institution in Miyazaki Prefecture from 2015 to 2019. Renal Replacement Therapy, 2022, 8, .	0.3	1
1032	Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan. Nephrology Dialysis Transplantation, 2023, 38, 414-424.	0.4	6
1040	Malignant hypertension: a type of IgA nephropathy manifestation with poor prognosis. Nefrologia, 2015, 35, 42-9.	0.2	8
1041	Hemolytic Uremic Syndrome in Children. , 2023, 56, 415-422.		2
1043	Postsurgical Thrombotic Microangiopathy and Deregulated Complement. Journal of Clinical Medicine, 2022, 11, 2501.	1.0	1
1044	Modern Approaches to the Management of Children with Atypical Hemolytic Uremic Syndrome. PediatriÄeskaÂ¢ FarmakologiÂ¢, 2022, 19, 127-152.	0.1	1
1045	Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. , 2022, 1, .		55
1046	Complement Mediated Endothelial Damage in Thrombotic Microangiopathies. Frontiers in Medicine, 2022, 9, 811504.	1.2	11

#	Article	IF	Citations
1047	Complement Gene Variant Effect on Relapse of Complement-Mediated Thrombotic Microangiopathy after Eculizumab Cessation. Blood Advances, 2022, , .	2.5	2
1048	Autoimmunity and its correlation to inflammatory vascular diseases. , 2022, , 189-228.		0
1049	The Complement System in the Modern Era of Kidney Transplantation: Mechanisms of Injury and Targeted Therapies. Seminars in Nephrology, 2022, 42, 14-28.	0.6	3
1050	Copy number variation analysis using next-generation sequencing identifies the CFHR3/CFHR1 deletion in atypical hemolytic uremic syndrome: a case report. Hematology, 2022, 27, 603-608.	0.7	2
1051	Immuneâ€mediated thrombotic thrombocytopenic purpura prognosis is affected by blood pressure. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	1.0	4
1054	Tacrolimus-Induced Thrombotic Microangiopathy After Orthotopic Heart Transplant: A Case Report. Cureus, 2022, , .	0.2	1
1055	The Importance of Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome. Cureus, 2022, , .	0.2	0
1056	A new pathological perspective on thrombotic microangiopathy. Kidney Research and Clinical Practice, 2022, 41, 524-532.	0.9	7
1057	Novel Complement C5 Small-interfering RNA Lipid Nanoparticle Prolongs Graft Survival in a Hypersensitized Rat Kidney Transplant Model. Transplantation, 2022, 106, 2338-2347.	0.5	6
1058	Atypical hemolytic uremic syndrome after myomectomy: A case report. Case Reports in Women's Health, 2022, 35, e00424.	0.2	1
1059	Thrombotic Microangiopathy Syndromesâ€"Common Ground and Distinct Frontiers. Advances in Chronic Kidney Disease, 2022, 29, 149-160.e1.	0.6	7
1060	Dengue Infection - Recent Advances in Disease Pathogenesis in the Era of COVID-19. Frontiers in Immunology, 0, 13, .	2.2	7
1061	The Complement System in Metabolic-Associated Kidney Diseases. Frontiers in Immunology, 0, 13, .	2.2	5
1062	Retrospective study of 59 cases of cancer-associated thrombotic microangiopathy: presentation and treatment characteristics. Nephrology Dialysis Transplantation, 0, , .	0.4	0
1063	Early graft loss due to acute thrombotic microangiopathy accompanied by complement gene variants in living-related kidney transplantation: case series report. BMC Nephrology, 2022, 23, .	0.8	2
1064	Editorial: Complement and COVID-19 Disease. Frontiers in Immunology, 0, 13, .	2.2	1
1065	Complement C3-targeted therapy in C3 glomerulopathy, a prototype of complement-mediated kidney diseases. Seminars in Immunology, 2022, 60, 101634.	2.7	4
1066	Soluble concentrations of the terminal complement complex C5b-9 correlate with end-organ injury in preeclampsia. Pregnancy Hypertension, 2022, 29, 92-97.	0.6	1

#	Article	IF	Citations
1067	The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients: a systematic review. Pediatric Nephrology, 2023, 38, 61-75.	0.9	5
1068	The favorable outcome of subsequent pregnancy in a patient with a history of obstetric atypical hemolytic uremic syndrome. AlÊ¹manah KliniÄeskoj Mediciny, 2022, 50, 133-138.	0.2	0
1069	De novo systemicÂatypical hemolytic uremic syndrome in an ABO-incompatible living kidney transplant recipient with aÂnovel pathogenic CFHR1 gene mutation successfully treated with eculizumab: a case report. Journal of Nephrology, 0, , .	0.9	0
1070	Evaluation of Pharmacist Impact on Patients Initiating Eculizumab for Atypical Hemolytic Uremic Syndrome in the Inpatient Setting. Annals of Pharmacotherapy, 2023, 57, 506-507.	0.9	0
1071	Manipulating the complement system via Therapeutic plasmapheresis: Is there any therapeutic role?. Journal of Clinical Apheresis, 2022, 37, 529-530.	0.7	0
1072	Incidence of thrombotic microangiopathies in Quebec: insight from a laboratory centralizing ADAMTS-13 testing. Orphanet Journal of Rare Diseases, 2022, 17, .	1.2	0
1073	Targeted nanotherapy for kidney diseases: a comprehensive review. Nephrology Dialysis Transplantation, 2023, 38, 1385-1396.	0.4	2
1074	Bilateral Optic Disc Swelling in a Patient With Atypical Hemolytic Uremic Syndrome. Journal of Neuro-Ophthalmology, 2024, 44, e37-e39.	0.4	0
1075	Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper. Molecular Therapy - Methods and Clinical Development, 2022, 26, 471-494.	1.8	20
1076	Clinical Utility and Potential Cost Savings of Pharmacologic Monitoring of Eculizumab for Complement-Mediated Thrombotic Microangiopathy. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2022, 6, 458-464.	1.2	3
1077	Evaluating the clinical utility of measuring levels of factor H and the related proteins. Molecular Immunology, 2022, 151, 166-182.	1.0	6
1078	Thrombotic Thrombocytopenic Purpura, Atypical Hemolytic Uremic Syndrome, and Spectrum of Thrombotic Microangiopathy. , 2022, , 595-635.		0
1079	An Infant Case of <i>Streptococcus Pneumoniae</i>-Associated Thrombotic Microangiopathy with Heterozygous <i>CFI</i> Mutation and <i>CFHR3-CFHR1</i> Deletion. Tohoku Journal of Experimental Medicine, 2022, , .	0.5	2
1080	Thrombotic Thrombocytopenic Purpura, Atypical Hemolytic Uremic Syndrome, and Spectrum of Thrombotic Microangiopathy. , 2022, , 1-42.		0
1081	A Guide for Adult Nephrologists and Hematologists to Managing Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy in Teens Transitioning to Young Adults. Advances in Chronic Kidney Disease, 2022, 29, 231-242.	0.6	0
1082	Simultaneous Cases of Carfilzomib-Induced Thrombotic Microangiopathy in 2 Patients With Multiple Myeloma. , 2022, , .		0
1083	Severe refractory warm autoimmune haemolytic anaemia after the SARS-CoV-2 Pfizer-BioNTech vaccine (BNT162b2 mRNA) managed with emergency splenectomy and complement inhibition with eculizumab. BMJ Case Reports, 2022, 15, e250774.	0.2	3
1084	Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study. BMJ Open, 2022, 12, e054536.	0.8	2

#	Article	IF	Citations
1085	The complement C3-complement factor D-C3a receptor signalling axis regulates cardiac remodelling in right ventricular failure. Nature Communications, 2022, 13, .	5.8	8
1086	Diagnosis and treatment of thrombotic microangiopathy. International Journal of Laboratory Hematology, 2022, 44, 101-113.	0.7	15
1087	The role of the complement system in kidney glomerular capillary thrombosis. Frontiers in Immunology, 0, 13, .	2.2	5
1088	Atypical hemolytic-uremic syndrome: evolution of treatment and impact of clinical and genetic characteristics on possibility of eculizumab withdrawal. Nephrology (Saint-Petersburg), 2022, 26, 19-29.	0.1	0
1089	Atypical Hemolytic Uremic Syndrome after SARS-CoV-2 Infection: Report of Two Cases. International Journal of Environmental Research and Public Health, 2022, 19, 11437.	1.2	4
1090	Coronavirus Disease 2019-Associated Thrombotic Microangiopathy: Literature Review. International Journal of Molecular Sciences, 2022, 23, 11307.	1.8	7
1091	Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report. Frontiers in Immunology, 0, 13, .	2.2	13
1092	Atypical hemolytic uremic syndrome: Consensus of diagnosis and treatment in taiwan. Journal of the Formosan Medical Association, 2022, , .	0.8	4
1093	The complement system in antineutrophil cytoplasmic antibody-associated vasculitis: pathogenic player and therapeutic target. Current Opinion in Rheumatology, 2023, 35, 31-36.	2.0	3
1094	Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study. Kidney International Reports, 2023, 8, 91-102.	0.4	12
1095	Haemolytic uraemic syndrome. Lancet, The, 2022, 400, 1722-1740.	6.3	19
1096	Comparison of Kidney Transplantation Outcomes Between Patients with and Without Pre-transplantation Bariatric Surgery: a Systematic Review. Obesity Surgery, 2022, 32, 4066-4081.	1.1	2
1097	How I diagnose and treat atypical hemolytic uremic syndrome. Blood, 2023, 141, 984-995.	0.6	12
1098	Hemolytic-Uremic Syndrome in Children. Pediatric Clinics of North America, 2022, 69, 1181-1197.	0.9	3
1099	Eculizumab as rescue therapy in a kidney transplant recipient with atypical hemolytic uremic syndrome: a case report. Korean Journal of Transplantation, 2022, , .	0.0	0
1100	Kidney diseases. Immunological Reviews, 2023, 313, 239-261.	2.8	8
1101	Comparison of outcomes after plasma therapy or eculizumab in pediatric patients with atypical hemolytic uremic syndrome. Clinical and Experimental Nephrology, 2023, 27, 161-170.	0.7	1
1102	Alternative pathway activation in pregnancy, a measured amount â€œcomplementsâ€•a successful pregnancy, too much results in adverse events. Immunological Reviews, 2023, 313, 298-319.	2.8	3

#	Article	IF	Citations
1103	Challenges in diagnostic testing of nephritic factors. Frontiers in Immunology, 0, 13, .	2.2	2
1104	The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review. European Journal of Health Economics, 2023, 24, 1151-1216.	1.4	2
1106	Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multiâ€protein cascade of the complement system. Immunological Reviews, 2023, 313, 376-401.	2.8	6
1107	Eculizumab-Every Fifteen Days Forever?. Kidney International Reports, 2023, 8, 4-7.	0.4	1
1108	A Patient with CFH Mutation. , 2022, , 31-35.		0
1109	Assessing the Impact of Prophylactic Eculizumab on Renal Graft Survival in Atypical Hemolytic Uremic Syndrome. Transplantation, 2023, 107, 994-1003.	0.5	6
1110	Trends and Outcomes of Hospitalizations Due to Hemolytic Uremic Syndrome: A National Perspective. Cureus, 2022, , .	0.2	0
1112	Diagnosis and Treatment for Shiga Toxin-Producing Escherichia coli Associated Hemolytic Uremic Syndrome. Toxins, 2023, 15, 10.	1.5	9
1113	COVID-19 vaccination and Atypical hemolytic uremic syndrome. Frontiers in Immunology, 0, 13, .	2.2	10
1114	Role of complement activation in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. Frontiers in Medicine, 0, 9, .	1.2	0
1115	What lies in-between: C3 glomerulopathy with non-hemolytic renal microangiopathy and an ultra-rare C3 variant. American Journal of the Medical Sciences, 2023, 365, 286-293.	0.4	2
1116	Case report of Salmonella derby septicemia complicated with co-occurrence of disseminated intravascular coagulation and thrombotic microangiopathy. BMC Infectious Diseases, 2022, 22, .	1.3	0
1117	Renal Thrombotic Microangiopathy: A Review. American Journal of Kidney Diseases, 2023, 81, 591-605.	2.1	23
1118	Pre-Existing Diabetes Mellitus, Hypertension and KidneyDisease as Risk Factors of Pre-Eclampsia: A Disease of Theories and Its Association with Genetic Polymorphism. International Journal of Environmental Research and Public Health, 2022, 19, 16690.	1.2	2
1119	Differentiating and Managing Rare Thrombotic Microangiopathies During Pregnancy and Postpartum. Obstetrics and Gynecology, 2023, 141, 85-108.	1.2	4
1121	Cold AIHA and the best treatment strategies. Hematology American Society of Hematology Education Program, 2022, 2022, 90-95.	0.9	2
1122	Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study. BMC Nephrology, 2023, 24, .	0.8	5
1123	Identification of potent siRNA targeting complement C5 and its robust activity in pre-clinical models of myasthenia gravis and collagen-induced arthritis. Molecular Therapy - Nucleic Acids, 2023, 31, 339-351.	2.3	3

#	Article	IF	Citations
1124	Case report: Thrombotic microangiopathy concomitant with macrophage activation syndrome in systemic lupus erythematosus refractory to conventional treatment successfully treated with eculizumab. Frontiers in Medicine, 0, 9, .	1.2	0
1125	The Role of Complement in Autoimmune Disease-Associated Thrombotic Microangiopathy and the Potential for Therapeutics. Journal of Rheumatology, 2023, 50, 730-740.	1.0	4
1127	Pharmacological Management of Atypical Hemolytic Uremic Syndrome in Pediatric Patients: Current and Future. Paediatric Drugs, 2023, 25, 193-202.	1.3	4
1128	Acute pancreatitis complicated by hemolytic uremic syndrome: a pediatric case. The Gazette of the Egyptian Paediatric Association, 2022, 70, .	0.1	0
1129	Primary Nephritic Syndromes (IgA Nephropathy and Complement- and Ig-Mediated Glomerular Disease) Tj ETQq0 0 0 rgBT /Overlock 10	3.0	0
1130	Thrombosis in Haematological Disorders: Tailored Management Approaches. European Medical Journal Hematology, 0, , 38-46.	0.0	0
1131	The first successful eculizumab rescue therapy of a kidney transplant recipient with atypical hemolytic uremic syndrome in South Korea: a case report. Korean Journal of Transplantation, 2023, , .	0.0	0
1132	Chemotherapy-Associated Thrombotic Microangiopathy. Kidney360, 2023, Publish Ahead of Print, .	0.9	4
1133	Complementâ€driven hemolytic uremic syndrome. American Journal of Hematology, 2023, 98, .	2.0	4
1134	Polly Wants a Cracker!. , 2023, , 495-501.		0
1135	Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy. Blood Cancer Journal, 2023, 13, .	2.8	4
1136	Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer. BioDrugs, 2023, 37, 311-329.	2.2	19
1137	Bilateral Proliferative Retinopathy as the Initial Presentation of Atypical Hemolytic Uremic Syndrome: A Case Report. Ophthalmic Surgery Lasers and Imaging Retina, 2023, 54, 297-300.	0.4	1
1139	Eculizumab in the management of drug-induced thrombotic microangiopathy: A scoping review of the literature. Thrombosis Research, 2023, 224, 73-79.	0.8	2
1140	Post-traumatic stress disorder and quality of life alterations in survivors of immune-mediated thrombotic thrombocytopenic purpura and atypical hemolytic and uremic syndrome. Journal of Critical Care, 2023, 76, 154283.	1.0	1
1142	An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome. Frontiers in Immunology, 0, 14, .	2.2	3
1143	The case for complement component 5 as a target in neurodegenerative disease. Expert Opinion on Therapeutic Targets, 2023, 27, 97-109.	1.5	0
1144	Complement Pathway Associated Glomerulopathies. European Medical Journal (Chelmsford, England), 0, , 30-38.	3.0	0

#	Article	IF	Citations
1145	Beyond IBD: the genetics of other early-onset diarrhoeal disorders. Human Genetics, 0, , .	1.8	1
1146	Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ, The, 0, , e069717.	3.0	33
1147	Absolutely Necessary!. , 2023, , 263-269.		0
1148	The Complement System in Kidney Transplantation. Cells, 2023, 12, 791.	1.8	4
1149	Ravulizumab for the treatment of myasthenia gravis. Expert Opinion on Biological Therapy, 2023, 23, 235-241.	1.4	1
1150	Eculizumab in the Treatment of Gemcitabine-Induced Atypical Hemolytic Uremic Syndrome. Cureus, 2023, , .	0.2	0
1151	Terminal Complement Activation Is Induced by Factors Released from Endplate Tissue of Disc Degeneration Patients and Stimulates Expression of Catabolic Enzymes in Annulus Fibrosus Cells. Cells, 2023, 12, 887.	1.8	2
1152	Molecular Advances in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease. International Journal of Molecular Sciences, 2023, 24, 5620.	1.8	1
1153	End-Stage Kidney Disease Resulting from Atypical Hemolytic Uremic Syndrome after Receiving AstraZeneca SARS-CoV-2 Vaccine: A Case Report. Vaccines, 2023, 11, 679.	2.1	5
1154	TMA in Kidney Transplantation. Transplantation, 2023, 107, 2329-2340.	0.5	3
1155	Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN). CKJ: Clinical Kidney Journal, 0, , .	1.4	0
1156	Pitfalls of Thrombotic Microangiopathies in Children: Two Case Reports and Literature Review. Diagnostics, 2023, 13, 1228.	1.3	2
1157	Utilizing therapeutic drug monitoring to optimize therapy with eculizumab and mycophenolate mofetil in a child with C3 glomerulonephritis. Pediatric Nephrology, 2023, 38, 3483-3487.	0.9	2
1158	A case report of an atypical haemolytic uremic syndrome in pregnancy: something wicked this way comes. BMC Anesthesiology, 2023, 23, .	0.7	1
1159	Atypical Hemolytic Uremic Syndrome in a Pregnant Patient with a Thrombomodulin Gene Variant Treated with Plasma Exchange and Eculizumab. American Journal of Case Reports, 0, 24, .	0.3	1
1160	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice â€“ Evidenceâ€Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. Journal of Clinical Apheresis, 2023, 38, 77-278.	0.7	81
1161	The Role of Complement in Kidney Disease. , 2023, , 593-603.		0
1162	Atypical Hemolytic Uremic Syndrome. , 2023, , 605-639.		0

#	Article	IF	Citations
1163	Drugs in treating paediatric acute kidney injury. Pediatric Nephrology, 0, , .	0.9	0
1164	SARS CoV-2 infection as a risk factor of preeclampsia and pre-term birth. An interplay between viral infection, pregnancy-specific immune shift and endothelial dysfunction may lead to negative pregnancy outcomes. Annals of Medicine, 2023, 55, .	1.5	2
1178	Complement therapeutics are coming of age in rheumatology. Nature Reviews Rheumatology, 2023, 19, 470-485.	3.5	2
1181	Editorial: Recent advances on renoprotection and kidney regeneration. Frontiers in Physiology, 0, 14, .	1.3	1
1198	The role of complement in kidney disease. Nature Reviews Nephrology, 2023, 19, 771-787.	4.1	7
1200	Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy. Drugs, 2023, 83, 1475-1499.	4.9	1
1202	Anti-CD20 antibodies in glomerular diseases, their resistance and reversal approaches. , 2024, , 313-334.		0
1207	Abdominal Infection. , 2023, , 253-277.		0
1208	Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities. Pediatric Nephrology, 0, , .	0.9	0
1209	Intensivmedizinisch bedeutsame Infektionserkrankungen. Springer Reference Medizin, 2023, , 1-17.	0.0	0
1217	Editorial: Role of complement activation in kidney diseases. Frontiers in Medicine, 0, 10, .	1.2	0
1218	Clinical advances in immunotherapy for immune-mediated glomerular diseases. Clinical and Experimental Medicine, 2023, 23, 4091-4105.	1.9	0
1239	Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nature Reviews Neurology, 2024, 20, 84-98.	4.9	4